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Abstract
Ninety percent of breast cancer-related mortalities result from metastasis. We have previously
demonstrated that stem-like ALDHhiCD44+ breast cancer cells are critical for metastasis, and
preferentially target the lung and bone marrow (BM). We hypothesize organ tropism occurs
through promotion of the ALDHhiCD44+ phenotype. Using a 2D ex vivo model, lung and BM
conditioned media (CM) were utilized to assess their influence on stem-like phenotype and
behavior. Exposure of human breast cancer cells to lung-CM significantly decreased the
proportion of cells with a stem-like ALDHhiCD44+ phenotype, decreased expression of cancer
stem cell (CSC)-related genes, and increased gene expression related to migration (p<0.05).
Lung-CM also induced a viable non-adherent subpopulation that expressed significantly
decreased CD44 expression and was unable to form mammospheres (p<0.05). Analysis of
lung-CM revealed presence of proteins related to migration, adhesion, and stemness. Taken
together, the lung microenvironment may promote metastasis of breast cancer cells in a CSCindependent manner.
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INTRODUCTION

Cancer is devastating. It is the source of physical, emotional, and mental stress that not
only affects the immediate individual involved, but extends further to family and friends.
In 2017 alone, it is estimated that 206,200 Canadians will be diagnosed with cancer1. These
figures have increased by nearly 10,000 new diagnoses within the past two years2.
Unfortunately, these figures are expected to rise by an additional 20% by 2020 largely due
an aging and growing population3. Greater emphasis on cancer prevention, adopting a
healthy lifestyle, and earlier detection is necessary to counter such undesirable outcomes3.
Breast cancer is the most common malignancy in women worldwide4. Despite its high
prevalence, patient prognosis is strong with 5-year survival rates nearing 99% when
localized to the breast5. Once the cancer leaves the confines of the breast, the chances of
surviving this drastically decrease5. In fact, the dissemination of cancer from the primary
affected region to distant organs accounts for 90% of all cancer related deaths6. Recently,
it has been proposed that a rare population of tumour cells, commonly referred to as cancer
stem cells, may be mediating metastasis and secondary tumour formation7. Therefore,
mortality related to breast cancer rarely occurs as a result of the primary tumour, but rather
the cascading effect of multiple organs becoming compromised, including the lung and
bone 8-10.
The focus of this thesis is to investigate the importance of the native lung and bone marrow
microenvironments in promoting rare, highly malignant cells to target these organs as
likely sites of metastasis. Understanding the role of the microenvironment is crucial to gain
a comprehensive understanding of cancer metastasis.
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LITERATURE REVIEW
Cancer

The term “cancer” encompasses a subset of diseases that are characterized by atypical cell
growth and proliferative patterns. As these aberrant cells develop, they acquire genetic
disruptions that enable sustained proliferative signaling and evasion of growth
suppressors11. Most often, the onset of this disease begins once genes involved in cell cycle
regulation become mutated and dysfunctional. These genes are most often classified either
as oncogenes or tumour suppressor genes. Once mutated, oncogenes become activated,
giving cells the ability to induce uncontrolled cell growth12. In contrast, mutations in
tumour suppressor genes may render normal cells incapable of DNA repair required to
regulate cell growth13. It is likely that oncogene activation and tumour suppressor gene
inactivation occur simultaneously as cancer progresses, ultimately resulting in tumour
formation14.
Tumours can be characterized by their benign or malignant nature, with the latter capable
of invasive traits that represent the hallmarks of cancer. A growth that is neither invasive
to surrounding or distant regions, such as a common wart, is considered benign and does
not pose a significant health risk11. In rare cases, benign tumours may impinge on blood
vessels or nerves that supply organ systems. These instances are considered higher risk and
require resection, however they are not considered malignant tumours15. Malignant
tumours tend to be life-threatening due to the capacity to leave the primary site and invade
into surrounding tissues or distant secondary sites of the body via access to systemic
circulation15. These tumours are referred to as malignant cancers and require early
detection and subsequent treatment to provide the best prognosis for patients. In later stages
of tumour progression, if the tumour has spread to distant sites, both primary and adjuvant
treatments (e.g. tumour resection, radiation, hormonal therapy, or chemotherapy) become
far less efficient at easing tumour burden16. Together, inefficiencies in treatment strategies
and efficacy leave both patients and the healthcare system in distress.
In 2017 alone, 1 in 4 Canadians will no longer be responsive to traditional cancer treatments
and will eventually succumb to the disease1. Further, the Canadian Cancer Society
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estimates that 1 in 2 Canadians will develop cancer within their lifetime, a value that is
increased from a 1 in 2.5 frequency just two years ago1,2. Similarly, the overall 5-year
survival rates in cancer patients have also decreased from 63% in 2015, to 60% in 20171,2.
Despite advances in targeted treatment and enhanced screening techniques, cancer is
proving to be relentless. If these patterns persist, cancer-associated deaths will account for
30% of Canadian premature deaths in 2017, 1. Premature deaths are measured by potential
years of life lost (PYLL) and account for deaths occurring at younger ages, a vital statistic
when assessing economic health for any given country. Between 2010 and 2012, cancer
represented the largest PYLL among Canadians, with 1.5 million years lost due to cancer1.
Due to a loss in productivity associated with high PYLL values, not only is the growing
Canadian economy impacted, but these patients also pose a significant financial burden on
the healthcare system. In 2008, the Public Health Agency of Canada estimated that $3.8
billion was devoted to direct healthcare costs for cancer patients (hospitalization,
treatments, etc.), while an additional $586 million was lost to indirect costs associated with
decreased economic productivity17. Considering that cancer diagnoses have increased in
recent years, the economic impact of cancer is expected to increase steadily with time.

Breast Cancer
The breasts are two prominences situated on the ventral torso of primates, morphologically
identical in both male and female offspring. Once females enter puberty, secretion of sex
and growth hormones (namely estrogen) promote mammary development. Subcutaneous
adipose tissue within the breast supports a network of ductal and lobular tissue, that
together, comprise the feeding mammary gland. The lobular epithelium of the breast serves
a lactiferous function, producing and secreting milk down the ductal epithelium for
expulsion out the nipple by contracting myoepithelial cells

18

. Due to hormonal cycling

involved in mammary development and throughout child-bearing years, the lobular and
ductal cells are most susceptible to tumour formation, and cancers that arise are termed
lobular or ductal carcinomas respectively16. So long as the tumour is confined to primary
breast tissue, the 5-year survival rate is an exceptional 98.6% among females5.
Unfortunately, this prognosis significantly decreases to ~25% once the cancer
metastasizes, spreading from the breast tissue and reaching secondary sites5. The most
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aggressive cases of breast cancer involve secondary tumour formation at distant organs,
resulting in significantly reduced organ function.

Histopathology and Molecular Subtypes
Recent findings regarding tumour heterogeneity suggest that each tumour is distinct and
unique from patient-to-patient. This further extends into distinctions between multiple
tumours identified within a single individual. Upon histopathological analyses of biopsied
tumour samples from the breast, inter-tumour heterogeneity is evident19. Histopathology
provides a rudimentary understanding of the cell subpopulations involved in tumour
development, their morphology, and predicting aberrant growth patterns. The main
purpose of this technique is to distinguish whether the breast tumour is originating from
ductal or lobular tissue architecture20. At the time of detection, ductal or lobular carcinomas
in situ (DCIS or LCIS respectively) are non-invasive as they remain confined to epitheliallined compartments within the mammary tissue20. Surgical resection and localized therapy
strategies such as radiation are highly effective and demonstrate strong patient prognosis
with a 99% survival outlook over five years21. Unfortunately, more than half of breast
cancer incidences are invasive ductal or lobular carcinomas (IDC or ILC) upon initial
diagnosis22. Tumours that have spread from epithelial-lined compartments of the mammary
tissue into the stroma are classified as invasive carcinomas through histopathological
analyses20. The associated treatment strategies for patients with IDC or ILC are less
effective and become limited as the tumour spreads from the primary tissue. A lack of
targeted therapies for invasive carcinomas is reflected in the 5-year survival rates dropping
to near 25% once the tumour has acquired invasive potential21.
In addition to histopathological distinction between breast cancer tumours, molecular
classification of breast cancer cells has provided further insight regarding the cells
propagating tumour growth and development. Among the invasive incidences of breast
cancer, the four main molecular subtypes of interest are: Luminal A, Luminal B, HER2enriched and basal-like (or triple-negative; TN) breast cancer23. The basis of this
classification system is dependent on cell surface expression of hormonal receptors and
intrinsic proliferation status of the cell. Luminal A breast cancer cells have a distinct
phenotype expressing receptors for the hormones estrogen and progesterone (ER+ and
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PR+), and lacking human epidermal growth factor receptor 2 (HER2-)24. Breast cancer
cells with a high proliferative (Ki67) index and/or expressing HER2, in addition to both
ER+/PR+, are classified as the Luminal B subtype. Both luminal A and B breast cancers
have been associated with positive survival outcomes24,25. Because both Luminal A and B
subtypes are ER+, hormone therapy is highly effective to treat patients, particularly in the
adjuvant setting19. Despite their similarities, Luminal B breast cancer cells are genetically
altered from the Luminal A subtype, resulting in poorer prognosis than those affected by
Luminal A breast cancer26. Further, the HER2+ breast cancer subtype lacks expression of
both ER and PR, rendering these cells unresponsive to targeted hormone therapy24.
Together with increased proliferation within this subtype, HER2+ breast cancer cells tend
to metastasize and spread more readily to surrounding tissues, resulting in poorer patient
prognosis relative to luminal breast cancers23. Inhibition of HER2+ ligand-receptor
interactions using HER2-targeting agents such as trastuzumab and lapatinib has improved
overall patient survival and time-to-disease progression, however many patients will
acquire resistance to therapy over time27.
Perhaps the most difficult breast cancer subtype to treat is the TN breast cancer subtype
which lacks the cell surface receptors found on the aforementioned breast cancer subtypes
(ER-/PR-/and HER2-)24. Often the most aggressive subtype of breast cancer, TN breast
cancer patients are highly prone to metastases which results in the poorest prognosis28.
Despite some TN breast cancers being initially responsive to traditional chemotherapy, a
hallmark of TN breast cancer is their high likelihood of distant recurrences within 3-years
of initial diagnosis29. As endocrine treatment strategies targeting ER/PR/ or HER2 are
ineffective on the TN subtype, central pathways involved in proliferation, growth and
migration are being actively investigated as potential targets30.
Although our understanding of molecular breast cancer subtypes has provided avenues for
clinical intervention, it is important to consider intra-tumour heterogeneity as a factor for
disease recurrence post-treatment. Cells from different regions of a solid breast tumour
have shown varying levels ER, PR, and HER2 cell surface expression which is consistent
with intra-tumour heterogeneity31. Thus, when investigating a heterogenous tumour, it is
important to consider that each population of cells has a distinct composition that may
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modulate tumour progression through intrinsic factors such as migration and/or invasion19.

Epithelial-to-Mesenchymal Transition
Given the anatomical composition and functional nature of mammary tissues, primary
tumours developing in the breast are epithelial-derived and termed carcinomas32.
Understanding how healthy epithelial cells function to maintain homeostasis is necessary
to predict changes in epithelial function in a diseased state. The epithelial cell utilizes
networks of cell-cell and cell-extracellular matrix (ECM) interactions to provide apicalbasal cell polarity. Desmosomes, adherens junctions and gap junctions are protein
complexes that maintain physical association between adjacent epithelial cells (cell-cell),
while cell-ECM interactions are necessitated by integrins and cell adhesion molecules
(CAMs)33,34. In a dynamic and invasive tumour microenvironment, extracellular cues
reduce characteristic epithelial cell-cell and cell-ECM interactions, and can induce a
mesenchymal cell phenotype35. The epithelial-to-mesenchymal transition (EMT) and its
reverse process, mesenchymal-to-epithelial transition (MET) describe this transformation
from one phenotype to another7. Once in the mesenchymal state, these cells lack apicalbasal polarity and possess increased migratory and invasive potential36,37. The role of EMT
and MET were first documented in embryogenesis, but the importance of these processes
further translates into cancer progression, and subsequently metastasis7,38. Cancer
progression requires cells of the primary tumour to disassociate and invade into the
surrounding stroma. This process of invasion is mediated in part by the loss of cell-cell
adhesions, which enhances cellular motility, while deterioration of cell-ECM interactions
allows catabolic cell secretions (e.g. matrix metalloproteinases; MMPs) to penetrate the
basement membrane34,37. As tumourigenic cells penetrate the porous basement membrane
and extend into the surrounding stroma, early stage carcinomas become invasive
malignancies7. In order to support tumourigenic growth, invading cells secrete angiogenic
factors (such as vascular endothelial growth factor [VEGF] and transforming growth factor
beta [TGF-β]) to support vascular growth necessary for nutrient delivery towards the
tumour34,37. Although recent studies document maintained tumour progression in the
absence of vascular recruitment (hypoxic conditions), vascular growth is necessary for
tumourigenic cells to invade systemic circulation and metastasize to distant sites34,37,39.
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Metastasis
The spread of cancer from a primary tumour to a distant secondary site is referred to as
metastasis, or metastatic disease. Although treatment strategies targeting the primary
tumour are highly efficient, nearly 30% of women diagnosed with early-stage breast cancer
will ultimately develop metastatic lesions40-42. For tumourigenic cells to metastasize, they
must leave the primary site and enter systemic circulation by directly invading the
surrounding vasculature, or indirectly through the lymphatic system43. As previously
mentioned, the invasive behaviour of cancer cells induced by EMT and other mechanisms
allows cancer cells to invade the surrounding stroma. Together with enhanced vascular
recruitment (angiogenesis and vasculogenesis) surrounding the primary tumour site, cancer
cells further develop means to enter into the vasculature/lymphatics and leave the primary
site43-45.
Millions of cells are capable of dissociating from the primary tumour and entering the
vasculature every day. However, the relative incidence of metastatic tumour development
is rare, suggesting that the metastatic process has inefficiencies42. As tumour cells
intravasate into the circulation, experimental studies have shown that >80% of these cells
can survive the shear and compressive stress associated with the circulatory phase of
metastasis41,42,46. The majority of these circulating tumour cells (CTCs) arrest in the first
capillary bed they encounter, while others remain selective for specific organ
microenvironments such as the bone, lung, and brain47-49. Only after successful
extravasation, whereby the CTCs exit the circulation and invade the distant organ, can
secondary tumour formation become possible43. Despite the large number of cells that
survive the circulatory phase of metastasis and successfully extravasate at the secondary
site, the inefficiencies associated with metastasis are highlighted when assessing tumourinitiating potential at the distant tissue. Experimental studies have shown that only ~2% of
cancer cells that successfully reach the secondary tissue microenvironment have the
capacity to initiate a new tumour, and <0.1% of cells can persist into the successful
formation of macrometastases42. These inefficiencies suggest that aspects of the metastatic
microenvironment and/or characteristics of cancer cells can contribute to the success or
failure of metastasis.
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Organ Tropism of Metastasis
In the event of metastasis, patterns of cancer dissemination to secondary sites are not
random, but rather coordinated50. Many cancers have shown preferential metastatic
capacity towards particular organs, a process referred to as organ tropism. Among the
various cancer subtypes, the patterns of organ tropism are variable and dependent on the
cancers’ origin. Some cancers predominantly metastasize to a specific organ (e.g. prostate
cancer metastasizing to the bone), while other cancers follow a sequential pattern of
metastasis (e.g. colorectal cancer often forms secondary metastases in the bone  lung 
brain)51. As each organ differs in anatomical position, blood/nutrient supply, and organ
microenvironment composition, invading tumour cells face different demands based on the
target organ. Clinically, breast cancer metastasis has demonstrated preferential metastasis
to the lung, bone, liver, brain and lymph nodes52.
Two competing theories that attempt to elucidate mechanisms involved in organ-specific
metastasis are Stephen Paget’s “seed and soil” hypothesis, and Ewing’s mechanical arrest
theory. Initially Paget, a British surgeon, theorized that cancer cells (the “seed”) require an
organ microenvironment (the “soil”) that can adequately support the growth of a metastatic
tumour53. Thus, for a metastatic tumour to successfully grow, there is a requirement for
favorable factors within the organ microenvironment capable of supporting tumour
formation. Strengthening Paget’s theory, recent findings in breast cancer research
demonstrate the luminal breast cancer subtype to preferentially metastasize to the bone,
while the HER2+ subtype often targets the liver54-56. Half a century later, James Ewing
proposed a novel mechanism dependent on physical characteristics of blood flow through
the circulatory system that dictate eventual sites of mechanical arrest. He proposed that
organs with the largest blood supply would be most prone to acquiring blood-borne
metastatic cells, leading to tumour cell arrest at the first capillary bed they encounter and
initiating secondary tumour formation57. In theory, Ewing’s mechanism holds strength,
however fails to fully explain clinical patterns of organ-specific metastasis. Despite
receiving a similar 10%-20% of blood volume, the liver, kidney and brain tissue each show
different patterns of susceptibility to metastasis development, highlighting the oversight in
Ewing’s theory58.

9

When considering a biologically relevant theory for organ tropism, the likely mechanism
is a combination of both Paget’s and Ewing’s hypotheses. A complex system that delivers
metastatic cells to different organ tissues based on relative blood supply, and then initiation
and maintenance of said tumour would be mediated by favourable interactions with the
soluble and insoluble factors provided by the organ.59,60.

The “Seeds”: Stem-Like Breast Cancer Cells
Research conducted by Massagué and colleagues uncovered an association between the
molecular characteristics of breast cancer cell (the “seed”) and the preferential tissue to
which the breast cancer cells metastasize52. Using in vitro and in vivo studies with the triplenegative MDA-MB-231 human breast cancer cell line, they demonstrated that specific
gene expression signatures can dictate a breast cancer cell’s preference to metastasize to
either the lung, the bone, or the brain47-49. However, this work did not take into
consideration the heterogeneous nature of primary metastatic breast cancer tumours.
Subsequent limiting dilution analyses in vivo confirmed this notion by demonstrating that
isolation and injection of low numbers of primary breast cancer cells into healthy immune
deficient mice resulted in only a small fraction of cells harnessing the ability to initiate and
produce a primary tumour61,62. These studies supported the idea that only a subset of cells
within a primary tumor have tumour-initiating capacity, suggesting that this rare
subpopulation may contain stem-like traits, often referred to as cancer stem cells (CSCs).
The concept of a CSC subpopulation within tumours first originated in hematologic
cancers, gaining credibility with evidence that only 1 to 4% of myeloma and leukemia
cancer cells demonstrated enhanced proliferative and colony formation potential63-65.
Although the cellular origins of cancer stem cells in some solid tumours remain
controversial, recent studies conducted by Blanpain et al have successfully demonstrated
that tumour populations in intestinal, prostate, and breast cancer can be traced back to a
stem/progenitor origin, reinforcing the validity of CSC model66.

Characterization of CSCs
Current methods of CSC characterization have been adapted from the pioneering field of
hematopoietic stem cells (HSCs). Discovered first by James Till and Ernest McCulloch
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during their investigation of hematopoietic system regeneration in vivo, a true HSC must
fulfill two requirements: the ability to self-renew and to maintain a multipotent state67. Selfrenewal refers to the cells’ ability to produce a sister HSC without losing multipotent
potential, while multipotency is the ability of a progenitor cell to differentiate into any
functional cell within a given lineage67,68. Originating from these well-characterized HSC
attributes, CSCs must be able to generate a heterogeneous tumour population
(differentiation) while concomitantly maintaining their own population (self-renewal)68.
Numerous studies have validated these stem cell characteristics to be true among a CSC
subpopulation, and in addition, have demonstrated that CSCs also possess enhanced drug
resistance, anchorage-independence, and increased migration relative to nonCSCs52,61,62,69,70. CSCs have also been associated with aggressive metastasis, and in many
instances, found to express molecular markers of EMT7. Considering the inefficiencies
previously mentioned regarding the metastatic process, it is reasonable to postulate that a
rare CSC subpopulation of primary breast cancer cells may also be able to establish and
drive distant secondary tumour development.
In light of their stem-like properties, CSCs can be isolated from a whole cell population
using similar molecular screening techniques used with HSCs. In breast cancer, CSCs from
patient tumours and various breast cancer cell lines have successfully been enriched for
based on high aldehyde dehydrogenase (ALDH) enzymatic activity and the co-expression
of the cluster of differentiation 44 (CD44) cell surface marker61,62,71.

2.6.1.1

ALDH

The ALDH family is made up of 19 evolutionarily conserved isoenzymes that are localized
intracellularly in the cytoplasm, mitochondria, and nucleus72. The main function of ALDH
is to catalyze the oxidation of aldehydes into carboxylic acids, along with other functions
such as ester hydrolysis and scavenging for hydroxyl radicals72. Of particular interest are
the isoenzymes (ALDH1A1, ALDH1A2, ALDH1A3, and ALDH8A1) involved in the
conversion of vitamin D to retinoic acid (RA), as they have recently been implicated in
cancer cell “stemness”73. The lipophilic RA molecule is capable of passive diffusion in a
paracrine or endocrine manner, resulting in induced transcription of biological genes
related to proliferation, differentiation, cell cycle arrest, and apoptotic pathways74. Notably,
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the human cytosolic ALDH1A subfamily (ALDH1A1 and ALDH1A3) are highly
expressed in early progenitor cells and have been documented to overlap with side
population cells capable of excluding Hoechst 33342 stain, another modality for
identifying stem-like cells61. Intrinsically high ALDH (ALDHhi) activity and Hoechst
33342 excluding stem-like side populations demonstrate increased expression of ABC
transporters, a feature thought to provide CSCs with chemo-resistance75. This protective
mechanism renders CSCs particularly resistant to conventional cancer therapies, permitting
relapse over complete remission, and prolonging tumour longevity7,76. Much of the
research concerning ALDH activity in cancer utilizes the metabolism of ALDEFLUOR™
substrate to isolate a subpopulation of tumourigenic cells with stem-like characteristics via
flow cytometry72. It was initially predicted that ALDH1A1 was responsible for the majority
of ALDEFLUOR™ metabolism, however recent evidence suggests ALDH1A3 is also
involved72,74. Considering the metabolism of ALDEFLUOR™ is non-specific, it is likely
that the ALDH activity detected in a cancer is due to the combined activity of two or more
ALDH isoforms72.
Analyses of intracellular ALDH activity in liver, lung, esophageal, and breast cancer cells
has been a useful tool to estimate how these tumourigenic cells may behave in vivo73. In
breast cancer, cells with elevated ALDH activity have demonstrated increased migratory
capacity and the ability to form mammospheres in vitro70,77. The importance of ALDH
activity in vivo was emphasized by Ginestier et al. after transplantation of 50,000 ALDHlo
human breast cancer cells into the mammary fat pad of immunocompromised mice was
insufficient for tumour formation, but transplantation as few as 500 ALDHhi cells resulted
in tumour formation within 40 days61,78. Both ALDH1A1 and ALDH1A3 have been
implicated in driving tumourigenesis after breast cancer cell transplantation in xenograft
models79,80. Moreover, Marcato et al demonstrated ALDH1A3 overexpression in human
breast cancer cells is case specific, as ALDH1A3 overexpression was tumour-promoting
in MDA-MB-435 and MDA-MB-231 cell lines, while tumour-suppressive in MDA-MB468 cells79. Clinically, Marselos et al identified ALDHhi activity to have a strong
correlation with metastatic lesions among patients with colon cancer, relative to healthy
adjacent tissues81. More recently, a study of 87 female patients diagnosed with metastatic
breast cancer found the incidence of ALDH1 expression significantly increased in the
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metastatic site (43.7%) compared to the primary tumour (28.7%), suggesting the
importance of ALDH1 in metastatic disease and secondary tumour formation82. With
accumulating evidence supporting the tumorigenic role of ALDH in patients with
metastatic breast cancer, a meta-analysis assessing 921 patients for elevated ALDH1A1
expression in breast cancer tumours concluded that ALDH1A1+ can be used as a biomarker
for the prediction of tumour progression and poor patient outcome83.

2.6.1.2

CD44

Membrane-spanning CD44 is a glycosylated cell surface receptor that has well-defined
roles in cell-cell and cytoskeletal cell-ECM interactions (via Rho GTPase signaling),
promotion of cell survival and invasion (via PI3/Akt and MAPK-Ras pathways).
Importantly, CD44 has a strong association with cell migration through interactions with
matrix metalloproteases (MMPs) and other matrix remodeling enzymes which together
coordinate cellular locomotion62,84. The principal ligand for CD44 is hyaluronic acid (HA),
a major component of extracellular matrices, which has also been reported to maintain long
term self-renewal85. Functional CD44 protein is encoded by a single gene with 20 exons,
where exons 1-5 and 16-20 comprise the standard isoform (CD44s), while exons 6-15 are
alternatively spliced to produce CD44 variants (CD44v)86. Although CD44s has been
implicated repeatedly in a variety of cancers, recent investigations have begun to examine
specific splice variants and their association in cancer progression87. CD44v4 in human
breast cancer cells was found to preferentially interact with E-selectin expressed human
umbilical vein endothelial cells (HUVECs) and promoted trans-migration88. Moreover, a
clinicopathologic study investigating the role of CD44v6 in 85 untreated primary breast
cancer patients reported that a decrease in CD44v6 mRNA correlated with poor survival89.
Due to conflicting data suggesting upregulation and/or downregulation of certain CD44v
isoforms implicated in cancer development, the CD44s isoform is most consistently used
for CD44 assessment90. Nevertheless, CD44 remains an important marker for identification
of tumourigenic cancer cell populations, both in vitro and in vivo. Research conducted by
Al-Hajj et al successfully identified a CD44+/CD24- subpopulation of breast cancer cells
with heightened CSCs characteristics. In vivo studies demonstrate that as few as 100
CD44+/CD24- cells were capable of forming tumours in mice, while the CD44-/CD24+
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subpopulation was unable to form tumours, even after injection of 500,000 cells62. These
findings suggest CD44 expression has an important role in tumour development.

Stem-Like Cancer Cells and Metastasis
Metastasis has been correlated with poor overall survival and mortality in several types of
cancers, a major obstacle in cancer treatment. The involvement of CSCs in metastatic
disease has received particular attention because they have been implicated in the initiation
of the metastatic cascade through EMT processes91. Interestingly, both ALDH and/or
CD44 have been used as markers for the identification of metastasis-prone cancer cell
subpopulations. Previous investigation conducted in the Allan lab by Croker et al found
breast cancer cells expressing the stem-like ALDHhiCD44+ phenotype demonstrated
enhanced metastatic behavior in vitro, as their ability to migrate and invade was
significantly increased relative to the non-CSC ALDHlowCD44- subpopulation70.
Moreover, these stem-like breast cancer cells exhibited increased ability to form
anchorage-independent colonies in vitro when compared to non-CSCs, suggesting these
cells could potentially colonize in a distant organ microenvironment after detachment and
dissemination70. Subsequent in vivo analyses confirmed the metastatic potential of stemlike breast cancer cells after orthotopic injection into the mammary fat pad of NOD/SCIDIL2Rγ mice led to increased spontaneous metastases to the liver, spleen, and most notably
the lung70. Not only did stem-like cells preferentially metastasize to these organs relative
to their non-CSC counterpart, the mean tumour volume and metastatic burden to the lung
was significantly increased in mice injected with the stem-like breast cancer cell
subpopulation70. Surprisingly, investigation of ALDH1A1 and ALDH1A3 isoenzymes
demonstrated differential roles related to their involvement in metastasis92. Using a
knockdown model, human breast cancer cells devoid of ALDH1A1 demonstrated a
significant reduction in their ability to migrate, and were less adherent in vitro92. In
contrast, knockdown of ALDH1A3 resulted in increased cell migration and adhesion in
vitro92. Knockdown of either ALDH1A1 or ALDH1A3 significantly decreased the number
of tumoursphere colonies formed in vitro92. Further, in a chick chorioallantoic membrane
(CAM) assay, ALDH1A1 knockdown resulted in reduced ability to of breast cancer cells
to extravasate from the vasculature, as well as reduced number of micrometastatic tumours
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with either knockout of ALDH1A1 or ALDH1A392. Collectively, ALDH activity among
CSC subpopulations has been demonstrated to be a critical factor in cancer dissemination
through coordinated activity of ALDH1 isoenzymes.
The concerns revolving around CSCs and metastasis extend past their ability to disseminate
and colonize distant organs. Tumour cells expressing stem-like characteristics present a
significant barrier between effective cancer therapy and improved patient prognosis91. As
CSC are postulated to have a slow rate of division and efficient efflux pumps capable of
removing toxic agents, traditional chemo- and radiation therapies become inadequate in
targeting CSC without off-target effects on healthy tissues91. Despite these limitations,
conventional therapy remains the first line of treatment and often results in cancer
recurrence due to a residual CSC subpopulation91. A subsequent study conducted by Croker
et al investigated the role of stem-like ALDHhiCD44+ breast cancer in therapy resistance.
By inhibiting ALDH enzymatic activity, CSCs became transiently sensitized to
chemotherapy (doxorubicin/paclitaxel) or radiotherapy measured by decreased cell
viability and colony formation in vitro93. Moreover, therapy resistance was attributed to
ALDH activity in part by the ALDH1A1 isoenzyme, and not ALDH1A3, demonstrated by
siRNA knockdown in vitro92. These findings suggest ALDH activity is an important
mediator of CSC therapy resistance, and has since been supported by several studies
reporting similar sensitization through ALDH inhibition94,95. Interestingly, a recent study
by Yang et al demonstrated that ALDH1A1 overexpression directly correlated with
increased activity of multidrug efflux pumps through phosphorylation by NIMA-related
kinase 2 (NEK2)96. An increase in efflux pump activity could support CSCs with high
ALDH activity to remove therapeutic toxins and allow the tumourigenic cell to continue
through to metastasis. Considering the importance of ALDH to drug resistance, without
ALDH inhibition in CSC subpopulations, tumorigenic cells remain resistant to therapy and
could be detrimental to patients as metastasis persists.
Taken together, the importance of CSC throughout metastatic progression is wellsupported. ALDH activity appears to provide CSCs with the capacity to support individual
steps of the metastatic cascade with regards to extravasation, migration, invasion, and
colony formation. Moreover, the function of ALDH in therapy resistance also promotes
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metastasis as CSCs become less likely to undergo apoptosis in response to therapy. Despite
their supportive role in the cancer progression, transient activation and inactivation of
cellular processes by CSCs is required to complete the metastatic cascade, suggesting CSC
plasticity as a key contributor to metastasis.

Plasticity of Stem-Like Cancer Cells
It is generally believed that normal development is largely unidirectional, where slowproliferating stem cell populations gives rise to highly proliferative progenitor cells,
ultimately producing terminally differentiated mature cell types that regulate organ
function97. The unidirectional nature of the cellular maturation process allows distinct cell
types with varying specialties to be present within a single organ system and maintain
functional homeostasis throughout the organisms lifespan97. This is especially clear in
organs such as the heart, where the annual cardiac myocyte turnover rate is ~1% per year
at age 20, drastically decreasing to ~0.4% after the age of 7598. That is not to say every
post-mitotic mature cell is incapable of proliferation. Within the pancreas, mature
pancreatic β-cells have been reported to expand their population through self-duplication
as opposed to stem-cell differentiation99. Instances such as self-duplication suggest mature
cells may have alternative options related to cell fate, despite having undergone terminal
differentiation. In particular, the concept of cell plasticity has received much attention
recently as it supports the notion that a cell can alter its phenotype or behaviour in response
to environmental queues100. The metabolic and epigenetic mechanisms required to induce
phenotypic plasticity were first documented during early embryogenesis, but have been
shown to re-activate during normal tissue regeneration, inflammation, and notably during
tumour development101.
The re-activation of cellular plasticity in tumour cells has been associated with acquisition
of a CSC state capable of therapeutic evasion, increased motility, and survival under
hypoxic conditions101. A prime example of tumour cell plasticity involves the
aforementioned EMT process. As cells transition from an epithelial state towards a
mesenchymal phenotype, intrinsic alterations are activated to induce changes in cell
phenotype and behaviour. In a study conducted by Liu et al, stem-like populations of breast
cancer cells expressing either a CD44+CD24- or ALDHhi phenotype were found to originate
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from one patient sample, yet represent two distinct subpopulations of breast CSCs
expressing

mesenchymal-like

(EMT)

and

epithelial-like

(MET)

phenotypes

respectively102. Interestingly, the EMT-CSC population was associated with a quiescent
state and preferentially localized to the invading tumour front, while the MET-CSC
phenotype was more proliferative and centrally localized102. During tumour development,
it was initially thought that EMT-CSC mediate invasion into surrounding tissues, while the
MET-CSCs drive tumour growth internally. As the tumour progresses, CSCs change states
in order to maintain invasion and proliferation accordingly. These findings suggest that
plasticity between an epithelial or mesenchymal state in breast CSCs is a transient
behaviour, rather than a fixed state. Thus, the role of CSC plasticity during tumour
propagation, invasion, and metastasis is an important consideration in patient treatment.
Furthermore, plasticity among CSC populations is also evident during therapy. Initially, it
was postulated that conventional therapeutic agents target and deplete non-CSCs, while
CSCs evade treatment and expand their population to form a more aggressive tumour upon
recurrence103. In a recent study conducted by Goldman et al, therapeutic treatment of
taxanes or anthracyclines on human breast cancer cells in vitro and in vivo not only induced
apoptosis in the majority of breast cancer cells, but also promoted the transition of nonCSCs towards a CSC state104. The therapy-resistant cells demonstrated increased
expression of breast CSC markers (CD44+CD24-) and augmented tumour growth, while
decreasing survival using patient derived xenograft models in mice. Indeed, these effects
were not due to an enrichment for the CSC population but rather a transition from nonCSC to CSC state, demonstrated by the dose-dependent increase of the CSC population
after acute low dose treatment104. Importantly, the plastic nature of CSCs was demonstrated
as removal of the chemotherapeutic agent reverted newly generated CSCs back to a nonCSC state104. CSC plasticity is not specific to breast cancer as similar findings have been
reported in prostate and ovarian cancer as well103. Nonetheless, the plasticity of the CSC
state highlights several complexities with regards to the identification of tumourigenic cells
and their subsequent response to conventional therapies.
Overall, plasticity among CSC populations plays a significant role in tumour progression,
metastasis, and therapeutic resistance. Despite the validation of tumourigenic CSCs in
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several studies, the scientific community has faced difficulties in identifying a universal
method for identification of elusive CSCs105. This is likely attributed to the search for a
specific CSC phenotype, rather than a highly plastic subpopulation of tumourigenic cells
capable of transitioning from one state to another.

The “Soil”: Organ Microenvironments
Cancer metastasis follows an organ-specific pattern of dissemination53. If the metastatic
site is compatible with the disseminated cancer cells, interactions between these cells and
the microenvironment will likely promote colonization and secondary tumour formation106.
Both clinical observation and experimental murine models suggest that organ-specific
metastasis occurs independent of anatomical position, rate of blood flow, and number of
cancer cells reaching the organ106. Using radiolabeled melanoma cells, cancer cell
progression through systemic circulation and successful delivery to key organs was
monitored after intravenous injection into murine models. Interestingly, radiolabeled
melanoma cells were selective in colonizing specific organs, demonstrating that although
tumour cells were capable of reaching the secondary organ, they required a congenial
microenvironment to support extravasation and tumour development107. More recently,
high expression of very late antigen 4 (VLA-4) on the endothelial cells surrounding the
lung, bone, and brain tissue have been demonstrated to support homing of circulating breast
cancer cells toward these organs through binding of their natural receptor, vascular cell
adhesion molecule-1 (VCAM-1), aberrantly expressed on the surface of breast CTCs108.
In our lab, research conducted by Chu et al has demonstrated the role of soluble organderived factors in promoting metastatic behaviour of breast cancer cells using a novel ex
vivo model system52. Clinically relevant organs representing common sites of breast cancer
metastasis (lung, bone marrow, liver, brain, LN) were harvested from female nude mice
and cultured to produce organ-specific conditioned media (CM) for use in functional
assays. The findings suggested that native soluble factors within organ-CM induced
chemotactic and proliferative functions among the MDA-MB-231, MDA-MB-468,
SUM149, and SUM159 human breast cancer cell lines analyzed52,109. Interestingly, these
patterns of migration and proliferation occurred in a manner that reflected in vivo patterns

18

of metastasis52.

The Lung Microenvironment and Lung Metastasis
The lungs are an indispensable organ involved in respiratory function, mediating the intake
of oxygen and disposal of carbon dioxide during normal physiological conditions110. The
functional anatomy of the lungs is divided into two zones. First air enters the conduction
zone in the upper respiratory tract, travelling down the trachea and directed into each lung
via the bronchi and terminal bronchioles110. The lower respiratory tract represents the
respiratory zone, where air is shuttled past the terminal bronchioles and into the respiratory
bronchioles, eventually reaching the alveolar ducts where individual alveoli necessitate gas
exchange through an expansive network of capillaries110. Interestingly, the lungs are often
implicated in various cancers, both as a direct cause from external factors (e.g. chemical
pollutants) and/or dysregulation of normal physiology111. In particular, the lungs are a
major site for tumour metastasis of breast and other cancers. A recent investigation of 1,088
medical records from non-metastatic breast cancer patients between 2004 and 2012
demonstrated that metastases to the lungs developed in 35% of patients, after a median
follow-up time of 6.9 years112. Although incidence of breast cancer metastases are higher
in bone marrow than in lung tissue, tumour formation in respiratory organs severely impact
the quality of life and are the leading cause of breast cancer related deaths 113. Often, the
more aggressive subtypes such as HER2+ and TN breast cancers metastasize to the lung
where they largely contribute to impaired respiratory function, leading to intense pain,
laboured breathing, and often hemoptysis114-117.
Behind the endothelial-lined capillary networks that supply the lung tissue with nutrients
and gas exchange, a porous alveolar microenvironment exists that is often targeted by
CTCs118. Once tumour cells have infiltrated the lung parenchyma, interactions between
invading tumour cells and the rich stromal microenvironment promote survival and
tumorigenic behaviour in the cancer cells51. Using a mouse mammary tumor virus
promoter-polyomavirus middle T-antigen (MMTV-PyMT) breast cancer model, secretion
of transforming growth factor-β3 (TGF-β3) by stem-like breast cancer cells demonstrated
direct stimulation of pulmonary fibroblasts to secrete extracellular matrix protein, periostin
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(POSTN), into the tumour-stroma microenvironment119,120. POSTN is a nonstructural
soluble protein that is present at low levels in healthy adults, but becomes significantly
overexpressed at sites of inflammation and within the tumour stroma121. Findings by
Malanchi et al demonstrate the necessity for POSTN in secondary tumour development as
knockout of POSTN in PyMT mice had no effect on primary breast tumour size and
volume, but significantly reduced incidence of pulmonary metastases120. More recently,
treatment of human periodontal ligament mesenchymal stem cells (PDLSCs) with
recombinant human periostin protein (rhPOSTN) accelerated migratory and proliferative
capacity among treated hPDLSCs122.
Further investigation of the lung microenvironment and its relation to tumour formation
has been modeled in vivo, however in vitro techniques for more detailed molecular
characterization of the lung microenvironment are limited as it is difficult to adequately
represent the complexities of native lung tissue in culture123. Utilizing the aforementioned
ex vivo model of organ-conditioned media, exposure to lung-CM has been shown to induce
migration of human breast cancer cell lines, as well as increase proliferative capacity in
two cell lines, MDA-MB-231 and MDA-MB-46852. In addition, the stem-like
ALDHhiCD44+ breast cancer subpopulation was exposed to organ-specific CM (bone
marrow, lymph, liver, lung, and brain) to assess how this subset responded to soluble
organ-derived factors. Interestingly, ALDHhiCD44+ breast cancer cells were found to
preferentially migrate towards lung-CM over all other organ conditions in vitro52. These
findings support observations by Croker et al, where ALDHhiCD44+ breast cancer cells
were observed to preferentially metastasize to the lung in vivo70.
To better understand the specific soluble factors within the lung-CM that promote
migration and growth of breast cancer cells, Chu et al carried out protein array analyses52.
They observed that lung-CM contained ~70 proteins that were absent in the basal media,
many of which have previously been shown to have specific roles in metastasis and
migration 48,49,52. Among the identified proteins, five ligands of CD44 (osteopontin [OPN],
basic fibroblast growth factor, and E-, L-, P-selectins) were identified to mediate growth
and metastasis of CD44+ breast cancer cells including stem-like ALDHhiCD44+ cells.
These findings provided insight to the lung microenvironment and its potential role in
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recruiting metastasis-initiating cells to the lung. However, little is known regarding the
processes leading to organ-specific metastasis in the context of the CSC model.

The Bone Microenvironment and Bone Metastasis
In addition to the lungs, bones of the axial skeleton are another major tissue susceptible to
metastasis in breast cancer patients. Approximately 60-85% of breast cancer patients
develop bone metastases which significantly affect the integrity and resilience of the bone,
resulting in chronic pain, bone resorption and pathological fractures in affected patients124.
Often metastatic colonies form in regions of the skeleton that are heavily vascularized such
as the pelvis, sternum, ribs, and particularly the marrow of long bones125. Structurally, the
framework of cancellous bone is organized in a three-dimensional lattice structure, akin to
lung tissue in that both are porous and supplied by a rich source of nutrients126. What sets
apart the bone marrow as a metastatic target from other tissues is its ability to support the
hematopoietic system and related stem cell niche. Within long bones (namely the femur),
osteoclasts, osteoblasts and bone marrow stromal cells are involved in HSC regulation.
Osteoblasts are specialized cells involved in the secretion of matrix proteins, and function
in a coordinated manner with bone-resorbing osteoclasts to maintain physiological
homeostasis. Interestingly, both cell types have been associated with supporting the HSC
niche within the marrow. Although somewhat controversial, osteoblasts have been reported
to interact directly with N-cadherin expressed on HSC to maintain quiescence and HSC
activity during serial BM transplantation127. Further, activated osteoblasts have been
demonstrated to secrete OPN, angiopoietin-1, and thrombopoietin, which have been
implicated in limiting HSC expansion and maintaining quiescence128-130. The active
resorption of bone by osteoclasts directly releases calcium into the bone marrow where
calcium receptors on HSCs bind and promote HSC localization through engraftment to the
endosteal surface of bone131. In addition, resorption of bone causes several chemokines
secreted by bone marrow stromal cells, such as C-X-C motif chemokine ligand 12
(CXCL12) which is also involved in HSC homing and mobilization, to be released into the
marrow132. Conveniently, CSCs from various cancers have been reported to express
elevated levels of chemokine C-X-C motif receptor 4 (CXCR4), which through interaction
with its ligand CXCL12, has been implicated in modulating the tumour microenvironment
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to support a CSC niche133. In a glioblastoma model, inhibition of CXCR4/CXCL12
interactions led to decreased self-renewal and survival among CSC populations,
emphasizing the importance of the bone marrow niche in supporting CSC populations134.
It would be beneficial to achieve a stronger understanding related to the interactions that
occur between HSC and the native bone marrow microenvironment as these interactions
may be translatable to CSCs.
As is the case with the lungs, the complexities of the bone marrow microenvironment make
it very difficult to accurately investigate its role in cancer metastasis and CSC maintenance
in vitro, resulting in the majority of research being performed in animal models135. Our
preliminary findings utilizing the ex vivo organ-CM model demonstrate MDA-MB-231 and
SUM159 breast cancer cell lines exposed to bone marrow-conditioned media (BM-CM)
exhibit enhanced migratory potential in both stem-like ALDHhiCD44+ and whole cell
populations136. Similar to the analysis of lung-CM protein content mentioned previously,
protein array analysis of BM-CM highlighted potential mediators of metastasis, including
the CD44 ligand OPN136. Notably, exposure of MDA-MB-231 breast cancer cells to BMCM induced stem-like behavior including tumorsphere formation and colony-forming
ability, mediated at least in part by OPN136. Although present in CM generated from bone
marrow stromal cells, the bone matrix and cancer cells themselves are also capable of
producing soluble OPN137. The relevance of OPN to bone metastatic capacity is
emphasized by experiments utilizing murine models deficient in, or overexpressing OPN,
where there was a strong correlation between OPN and the likelihood of skeletal
metastasis137.
Taken together, our previous findings from both the lung-CM and BM-CM protein arrays
combined with data gathered from functional assays suggests that proteins produced by the
lung and bone marrow support the growth and migration of stem-like ALDHhiCD44+ breast
cancer cells that facilitates their metastatic capacity towards these organs. However, the
role of these organ microenvironments not only supporting but promoting a stem-like
breast cancer phenotype requires further investigation, and this is the topic of this thesis.
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Study Rationale
Ninety percent of breast cancer-related mortalities result from metastasis, a process
whereby the primary tumour disseminates and targets distant secondary organs.
Interestingly, events leading up to secondary tumour formation have marked inefficiencies,
with only a very small proportion of primary tumour cells able to reach, persist and grow
into a secondary tumour138. We believe this rare subset of cells may be stem-like cancer
cells. CSCs possess unique capabilities of self-renewal and differentiation, and help to
potentiate the development of secondary tumours. Breast CSCs from patient tumours and
cell lines have been successfully isolated based on high ALDH enzymatic activity and coexpression of the cell-surface glycoprotein CD44. These two CSC markers actively provide
the cell with protective detoxifying mechanisms as well as enhanced metastatic capacity,
respectively52,76,84. We have previously observed that ALDHhiCD44+ cells preferentially
migrate and/or metastasize to the lung and bone marrow microenvironments, where
secondary tumours severely impact organ function. In addition, previous work in our lab
has demonstrated that bone marrow-conditioned media can enhance the stem-like behavior
of breast cancer cells. However, the specific role of the lung and bone microenvironments
promoting metastasis of stem-like ALDHhiCD44+ cells remain poorly understood.
Our preliminary studies have shown that the lung and bone marrow microenvironments
provide necessary factors to support the stem-like ALDHhiCD44+ breast cancer
subpopulation, following a hierarchical model (Figure 1). In this thesis, we propose that
the lung and/or bone microenvironments may induce cellular plasticity in breast cancer
cells to promote ALDHhiCD44+ phenotype and subsequent acquisition of metastasisinitiating capacity (Figure 1). Understanding whether organ microenvironments promote
stem-like phenotype and function could provide further insight into the mechanisms
underlying organ-specific breast cancer metastasis.
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Figure 1. The ALDHhiCD44+ phenotype in breast cancer cells enhances metastasisinitiating capacity. (A) In the primary breast tumor, ALDHhiCD44+ cells comprise a
subpopulation of the total tumor; the percentage of which may be higher in aggressive
tumors (i.e. triple-negative breast cancer). (B) Early dissemination steps in metastasis are
very efficient and may include both ALDHhiCD44+ and ALDHlowCD44- cells. However,
only breast cancer cells with an ALDHhiCD44+ phenotype can initiate and maintain
metastasis. We hypothesize that this may occur either via a hierarchical model, in which
ALDHhiCD44+ cells are pre-existing before entering the secondary site (i.e. lung) and
microenvironmental factors support their ability to initiate metastases; and/or via a
dynamic model, in which the influence of the lung microenvironment may facilitate
cellular plasticity to promote the development of an ALDHhiCD44+ phenotype and
acquisition of metastasis-initiating capacity. In both cases the population of ALDHhiCD44+
cells are enriched in the metastatic site and can generate a heterogeneous tumor.
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HYPOTHESIS AND OBJECTIVES
Hypothesis

The lung and bone microenvironments promote stem-like and metastatic behavior of
human breast cancer cells.

Objectives
To determine the role of lung and bone microenvironments in promoting (1) stem-like
phenotype, and (2) stem-like functional behavior of human breast cancer cells in vitro.
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MATERIALS and METHODS
Cell Culture and Reagents

Several genetically unique immortalized human breast cancer cell lines were used in this
study. The cell lines MDA-MB-468 (TN subtype), SUM159 (TN subtype), MDA-MB-231
(TN subtype) and MCF-7 (Luminal A subtype) are epithelial in origin and have adherent
culture properties. The metastatic capacity of these cell lines in vivo (from greatest to least)
are SUM159 > MDA-MB-231 > MDA-MB-468 > MCF-747,52,139. Human breast cancer
culturing conditions are described in Table 1. Media was purchased from Invitrogen
(Burlington, ON, Canada). Fetal bovine serum (FBS) was purchased from Sigma (St.
Louis, MO, USA) and VWR (Mississauga, ON, Canada). Tissue culture plastic was
purchased from NuncTM (Fisher Scientific, Ottawa, ON, Canada). Trypsin was purchased
from Invitrogen and used at a concentration of 0.25% in citrate saline. Ethylene diamine
tetraacetic acid (EDTA) was purchased from Bioshop Canada Inc. (Burlington, ON,
Canada) and used at a concentration of 2 mM in deionized water. Cells were cultured at
low passage numbers (<10) for all experiments and maintained under normal culture
conditions of 37°C and 5% CO2.

Lung and Bone Marrow Ex Vivo Model Systems
Using a novel technique adapted by Chu et al, lung-CM and BM-CM were generated as
described below and used to investigate the significance of organ-derived soluble factors
and their influence on stem-like breast cancer phenotype and function 52,136.

Organ Conditioned Media Generation
Healthy 5-7 week old female athymic nude mice (Hsd: Athymic Nude-Foxn1nu; Envigo,
Indianapolis, IN) were purchased and monitored under the guidelines of the Canadian
Council of Animal care as outlined by the protocol approved by the University of Western
Ontario Council of Animal care (protocol #2009-064; Appendix 1). Mice were euthanized
by CO2 inhalation and lungs, or tibia and femur were aseptically removed and
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Table 1. Human Breast Cancer Cell Lines and Culturing Conditions
Cell Line

Culturing Conditions

Source

MDA-MB-468

𝛼MEM + 10% FBS

MDA-MB-231

DMEM:F12 + 10% FBS

MD Anderson
Cancer Center

MCF7

DMEM + 10% FBS

Koropatrick Lab

SUM159

HAM F:12 + 5% FBS, 0.5% insulin,
0.1% Hydrocortisone, 1% HEPES

Asterand

MD Anderson
Cancer Center
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placed into pre-weighed 50-mL conical tubes with 30mL sterile phosphate-buffered
saline (PBS).

4.2.1.1

Lung Conditioned Media (Lung-CM)

Harvested lungs were washed three times in ice cold PBS before being dissociated into ~1
mm3 fragments. Lung tissues were weight-normalized by resuspension in a 4:1 media to
tissue (v/w) ratio in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12
(DMEM:F12) supplemented with Mito+ serum extender (1X, BD Biosciences,
Mississauga, Canada) and penicillin-streptomycin. Lung fragments and media were
cultured at 37°C and 5% CO2 for 24 hours. Following culturing, conditioned media (CM)
was harvested, diluted by three volumes of media and centrifuged at 900g for 15 minutes
at 4°C to remove residual cell debris. Lung-CM was passed through a 0.22μm syringe filter
(Corning, Germany), aliquoted and stored at -80°C until use. To account for mouse-tomouse variability, lung-CM from multiple mice was pooled prior to use in experimental
studies (Figure 2A).

4.2.1.2

Bone Marrow Conditioned Media (BM-CM)

Isolated tibia and femurs from mice were trimmed clean of excess muscle tissue and
epiphyses removed. Since the cellular content in bone marrow (BM) is lower than in other
organs, a different approach was used to generate BM conditioned media (BM-CM). Using
a 27-gauge x ½ inch needle, PBS was flushed through the shaft of each long bone. The
collected BM cells which had been previously characterized by Chu et al to be bone
marrow stromal cells (BMSC), were then centrifuged for 5 minutes at 1000g, resuspended
in DMEM + 10% FBS + pen/strep and incubated at 37°C + 5% CO2. BMSCs were seeded
at a concentration of ~1 x 107 cells/flask in T-75 flasks and cultured at 37°C and 5% CO2
for 2-3 passages. The BMSC monolayer was washed and finally exposed to DMEM/F12 +
Mito+ + pen/strep for 72 hours, after which BM-CM was collected by centrifugation at
900g for 15 minutes at 4°C, passed through a 0.22μm syringe filter (Corning, Germany)
and stored at -80°C until use. To account for mouse-to-mouse variability, BM-CM from
multiple mice was pooled prior to use in experimental studies (Figure 2B).
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Lung tissue was mechanically disassociated using a
surgical scalpel and cultured in serum free media for 24
hours prior to collection.

BM tissue was pushed out from the long bones and
mechanically disassociated using a 27-gauge x ½ inch needle,
followed by a 3-week culture period prior to collection.

Figure 2. Generation of organ-conditioned media. Healthy female nude mice were
euthanized by CO2 inhalation and organs were removed aseptically. (A) Harvested lungs
were washed, minced into ~1 mm3 fragments, and resuspended in a 4:1 media to tissue
(v/w) ratio for culturing at 37°C and 5% CO2 for 24 h. Following culture, lung-CM media
is collected and further diluted by three volumes of basal media. (B) Femurs and tibias
were excised from female nude mice and subject to bone marrow extraction using a
27gauge x ½ inch needle to flush out the BM contents. Collected cellular bone marrow
stromal cells (BMSC) were seeded and cultured for 2-3 passages before collection of BMCM. All organ-CM is centrifuged to remove cellular debris and subjected to sterile
filtration prior to use in experimental studies.
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Flow Cytometry Analysis
Flow cytometry was used to identify the frequency of ALDHhi, CD44+, and
ALDHhiCD44+cells from both the MDA-MB-468 and SUM159 breast cancer cell lines.
Initial seeding densities were determined based on 60% tissue culture confluency at a 48hour timepoint. MDA-MB-468 (4 x 105 cells) and SUM159 (1.5 x 105 cells) were seeded
and grown on 60 mm tissue culture dishes in regular growth media for 48 hours. Cells were
then washed with PBS and exposed to three different treatments: BM-CM, lung-CM, or
basal media as negative control. Cultured breast cancer cells were harvested using trypsin
(1x) after 24, 48, and 72 hours and labeled as described below.

The Aldefluor™ assay kit (StemCell Technologies, Vancouver, BC, Canada) was used to
assess ALDH activity. The Aldefluor™ kit uses an uncharged fluorescent ALDH substrate
[BODIPY-aminoacetaldehyde (BAAA)] that passively diffuses into cells. Cellular ALDH
activity converts uncharged BAAA molecules to negatively charged BODIPYaminoacetate (BAA-) molecules, preventing diffusion out of the cell. Trapped BAAmolecules increase green fluorescence in ALDHhi cells. Cells were kept on ice prior to
sorting to prevent the efflux of BAA- from labeled cells by ABC-transporters. In addition,
the AldefluorTM buffer contains a pharmacological inhibitor of ABC-transporters.
Approximately 2 x 106 cells were harvested, washed in PBS, centrifuged at 1000g for 5
min, resuspended in AldefluorTM buffer and incubated with Aldefluor™ substrate (10 µL
BAAA/106 cells). A control sample was also prepared in which 5 µL the specific ALDH
inhibitor diethylaminobenzaldehyde (DEAB; 1.5 mM) was co-incubated with Aldefluor™.
DEAB inhibits ALDH enzyme activity and allows BAAA to remain in its uncharged form
and passively diffuse out of the cell. Following a 45-minute incubation at 37°C, samples
were centrifuged (1000g for 5 min), washed with PBS/centrifuged (1000g for 5 min), and
resuspended with Aldefluor™ assay buffer. Subsequent labelling with 10 µL CD44phycoerythrin (PE; BD Biosciences) antibody was performed at 4°C for 30 min. Cells were
again washed with PBS/centrifuged (1000g for 5 min) and resuspended in assay buffer.
Following resuspension, 5 µL of 7-aminoactinomycin D (7-AAD; BD Biosciences) was
added to samples to monitor cell viability. Samples were stored on ice and analyzed by
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flow cytometry for intrinsic ALDH activity and/or CD44 cell surface expression using the
gating strategy illustrated in Figures 3, 4 and 5 (SUM159 cells; adherent MDA-MB-468
cells; and non-adherent MDA-MB-468 cells, respectively). Analysis was performed using
a Beckman Coulter FC500 flow cytometer, with acquisition analyses carried out using
Kaluza 1.5 software (Beckman Coulter, USA).

31

Figure 3. Representative flow cytometry gating strategy for analysis of ALDH activity
and/or CD44 cell surface expression in SUM159 human breast cancer cells. Whole cell
populations of SUM159 breast cancer cells were harvested and labelled with 7-AAD,
CD44-PE, and the Aldefluor™ assay kit. Analysis was performed using a three-colour
multi-parameter gating strategy on a Beckman Coulter EPICS XL-MCL flow cytometer.
(A) Viable cells were identified based on 7-AAD exclusion, and (B) gated based on
forward scatter. Cells satisfying viability criteria were then assessed for (C) ALDH activity
relative to a DEAB control, and (D) CD44 expression relative to a cells only control. (E)
Breast cancer cells expressing both high ALDH activity and CD44 expression were used
to identify the ALDHhiCD44+ phenotype. Analysis performed using 50,000 events.
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Figure 4. Representative flow cytometry gating strategy for Analysis of ALDH
activity and/or CD44 cell surface expression in adherent MDA-MB-468 human breast
cancer cells. Adherent whole cell populations of MDA-MB-468 breast cancer cell lines
were harvested and labelled with 7-AAD, CD44-PE, and the Aldefluor™ assay kit.
Analysis was performed using a three-colour multi-parameter gating strategy on a
Beckman Coulter EPICS XL-MCL flow cytometer. (A) Viable cells were identified based
on 7-AAD exclusion, and (B) gated based on forward scatter. Cells satisfying viability
criteria were then assessed for (C) ALDH activity relative to a DEAB control, and (D)
CD44 expression relative to a cells only control. (E) Breast cancer cells expressing both
high ALDH activity and CD44 expression were used to identify the ALDHhiCD44+
phenotype. Analysis performed using 50,000 events.
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Figure 5. Representative flow cytometry gating strategy for analysis of ALDH
activity and/or CD44 cell surface expression in non-adherent MDA-MB-468 human
breast cancer cells. Non-Adherent cell populations of MDA-MB-468 breast cancer cell
lines generated after exposure to organ-CM were harvested and labelled with 7-AAD,
CD44-PE, and the Aldefluor™ assay kit. Analysis was performed using a three-colour
multi-parameter gating strategy on a Beckman Coulter EPICS XL-MCL flow cytometer.
(A) Viable cells were identified based on 7-AAD exclusion, and (B) gated based on
forward scatter. Cells satisfying viability criteria were then assessed for (C) ALDH activity
relative to a DEAB control, and (D) CD44 expression relative to cells only control. (E)
Breast cancer cells expressing both high ALDH activity and CD44 expression were used
to identify the ALDHhiCD44+ phenotype. Analysis performed using 500,000 events.
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RT-qPCR Analysis
MDA-MB-468 and SUM159 cells exposed to lung-CM, BM-CM, or basal media for 24
hours were harvested (≤ 5 x 105 cells) and lysed using RLT lysis buffer (Qiagen, Germany).
Total RNA extraction was performed using a column based RNA purification method
(RNeasy® Micro kit, Qiagen, Germany). RNA quality and concentration was determined
using the NanoDrop One apparatus (Thermo Fisher Scientific, USA), and RNA was stored
at -80°C.

Analysis of ALDH1A1, ALDH1A3, and CD44 Gene
Expression
Subsequent cDNA synthesis was completed (Invitrogen, USA), combined with
Supergreen Mastermix (Wisent Bioproducts, CA) and custom primer sets that were
designed to detect ALDH1A1, ALDH1A3, and CD44 mRNA expression (Table 2).
Samples were loaded onto 96-well plates and loaded onto the Stratagene Mx3000p
instrument. The thermal profile setup began at 95 °C for 5 min to allow cDNA to
denature, followed by 40 cycles at 95 °C for 15 seconds and 60 °C for 30 seconds.
Relative quantification was performed using a standard curve method with serial dilutions
(1, 1:10, 1:100, 1:1000, 1:1 x 104). Data were analyzed using ΔCT values and transcript
levels normalized to the internal control glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). MXPro software (Agilent, CA, USA) was used for qPCR data analysis.

Quantitative RT-PCR Human Cancer Stem Cell® Array
RNA samples from MDA-MB-468 human breast cancer cells were harvested (~5 x 105
cells) after 24 hour treatment with basal media or lung-CM. Cells were then lysed using
RLT lysis buffer (Qiagen, Germany), followed by total RNA extraction performed using
column based RNA purification (RNeasy® Micro Kit, Qiagen, Germany). RNA quality
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Table 2. Gene List and Primer Sequences
Gene

ALDH1A1

Primer Sequence

Forward: 5’ – CGT TGG TTA TGC TCA TTT GGA A – 3’
Reverse: 5’ – TGA TCA ACT TGC CAA CCT CTG T – 3’

ALDH1A3

Forward: 5’ – ATG CGG ATT GCC AAA GAG GA – 3’

Source

Integrated DNA
Technologies (IDT)

Integrated DNA
Technologies (IDT)

Reverse: 5’ – AGC CAA CTT CAG GGC TTT GT – 3’

CD44

Forward: 5’ – GGG TGT ACA TCC TCA CAT CCA A – 3’

Integrated DNA
Technologies (IDT)

Reverse: 5’ – GCT CAC GTC ATC ATC AGT AGG G – 3’

GAPDH

Forward: 5’ – TTG CCC TCA ACG ACC ACT TTG T– 3’
Reverse: 5’ – AGG GGT CTT ACT CCT TGG AGG C– 3’

Integrated DNA
Technologies (IDT)

36

and concentration was determined using the NanoDrop One apparatus (Thermo Fisher
Scientific, USA), and stored at -80°C. Subsequent cDNA synthesis was completed using
the RT2 First Strand Kit (Qiagen, Germany), followed by RT-qPCR preparation using RT²
SYBR Green ROX qPCR Mastermix (Qiagen, Germany). Samples were then loaded onto
preset 96-well RT² Profiler™ PCR Array Human Cancer Stem Cells arrays (Qiagen,
Germany). The thermal setup began at 95 °C for 5 min to allow cDNA to denature,
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 30 seconds. RT-qPCR was
performed on the Stratagene Mx3000p instrument, with analysis of ΔCT values
performed using MXPro software (Agilent, CA, USA) and Qiagen’s online Data Analysis
Center. All transcript levels were normalized to the internal GAPDH control.

Cell Viability Assays
Trypan Blue Exclusion
MCF7, MDA-MB-468, MDA-MB-231, and SUM159 cells were cultured (37°C, 5% CO2)
and doubling time was analyzed to determine initial seeding densities that result in 60%
tissue confluency after 48 hours incubation at 37°C (2 x 105, 1 x 105, 7.5 x 104, and 7.5 x
104 cells respectively). Cells were seeded on 6-well plates and grown for 48 hours, allowing
cells to re-adhere and adjust to in vitro conditions. Cells were then washed with PBS x 2
and exposed to lung-CM, BM-CM, or basal media for an additional 48 hrs. Viability of
resulting non-adherent breast cancer cell subpopulations was performed by collecting 10
µL of media and combining with an equal volume of Trypan Blue (1X, St. Louis, MO,
USA). Total number of cells (live and dead) was enumerated using a hemocytometer under
a light microscope and percentage of viable cells was determined. Representative images
of floating and adherent cells were obtained using an inverted Olympus IX70 microscope.

LIVE/DEAD® Assay
Based on trypan blue cell viability analysis, MCF7 and MDA-MB-468 human breast
cancer cell lines were chosen as candidate cell lines to confirm non-adherent cell viability
using the fluorometric LIVE/DEAD® assay (Life Technologies, Burlington, ON, CA)
based on staining with two dyes. Calcein-acetoxymethyl (calcein-AM) is a polyanionic dye
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that is initially non-fluorescent, but once permeating the cell membrane of viable cells,
becomes enzymatically converted to its fluorescent form by ubiquitous intracellular
esterase activity. Conversely, ethidium homodimer-1 (EthD-1) functioned as a marker for
cell death. In living cells, with a functional plasma membrane, EthD-1 is excluded from
entering the cell. Once cells become damaged and the plasma membrane’s integrity is lost,
EthD-1 is able to penetrate and bind to nucleic acids which induce a 40-fold increase in
fluorescence in dead cells.
Cells were seeded onto T-75 tissue culture flasks at 3 x 106 and 2 x 106 cells, MCF7 and
MDA-MB-468 respectively. Cells were cultured for 48 hours, allowing cells to adjust to
the in vitro conditions. Cells were then washed with PBS x 2 and exposed to lung-CM,
BM-CM, or basal control media for an additional 48 hours. Media containing non-adherent
cells were harvested, centrifuged (5 minutes at 1000g), and washed in PBS x 3. The
collected cell pellet containing non-adherent cells became the experimental sample to be
tested for viability. From the adherent subpopulation, 2 x 106 viable cells were collected,
centrifuged (5 minutes at 1000g), washed in PBS x 3, and split into two individual tubes
labelled “live” and “dead”. The “live” tube provided a positive control. The “dead” tube
was centrifuged (5 minutes at 1000g) and the cell pellet was treated with 100µL IntraPrep
Reagent 1: Fixation (IntraPrep Permeabilization Reagent, Beckman Coulter, USA), and
covered at room temperature for 15 minutes to induce cell death. These “dead” cells
provided a negative control for the LIVE/DEAD® assay. A working solution of 2 µM
calcein-AM and 4 µM of EthD-1 LIVE/DEAD® reagent were combined. Using a 96-well
plate, 100µL of working solution was combined directly with 100µL of sample (1:1) in
each required well. Samples were covered and incubated at room temperature for 30
minutes.

4.5.2.1

LIVE/DEAD® Fluorescent Imaging

After incubation, 200µL of sample was loaded onto glass microscope slides and covered
with a 22mm glass coverslip. Images were acquired at 10x magnification using an upright
Olympus Provis microscope (Olympus) coupled with a Retiga 2000R charge-coupled
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device camera (QImaging, BC, Canada). Fluorescent images were captured using a RedGreen-Blue filter fitted to the Retiga 2000R camera.

4.5.2.2

LIVE/DEAD® Fluorescence Measurement of Viability

After incubation, the 96-well plate containing samples were inserted into a Synergy H4
Hybrid Reader (BioTek, USA). Sample excitation/emission (Ex/Em) wavelengths were
adjusted to 485nm/530nm and 530nm/645nm for each of the live/dead reporters, calceinAM and EthD-1 respectively. Sample fluorescence values were recorded and percent
viability (% Live Cells) was calculated.

Mammosphere Assay
MCF7 and MDA-MB-468 cells were cultured and doubling time was calculated to
determine initial seeding densities that result in 60% tissue confluency after 48 hours.
Based on doubling time, 3 x 106 and 2 x 106 cells were seeded on T-75 tissue culture flasks
(Corning, USA) and cultured for 48 hours respectively, allowing cells to adjust to the in
vitro conditions. Samples were then washed with PBS and exposed to lung-CM, BM-CM,
or basal media for an additional 72 hrs. Respective adherent and non-adherent cell
subpopulations were isolated from each treatment condition and counted manually using a
hemocytometer and trypan blue exclusion. Approximately 5 x 105 and 3 x 105 viable nonadherent cells could be expected from each T-75 tissue culture flask following 72-hour
lung-CM treatment of MDA-MB-468 and MCF7 cells, respectively. Basal and BM-CM
treatment rendered nearly 1.5 x 105 viable non-adherent cells in either cell line. For each
subpopulation and treatment condition, 1 x 103 viable cells were resuspended in
mammosphere media (500mL DMEM:F12, 2.5mL Insulin [1mg/mL], 400µL EGF
[25µg/mL], 200µL bFGF [25 µg/mL], 20mL of 10% BSA, 2mL B27). Subsequent serial
limiting dilutions of cells were carried out (1000 cells/well to 0.001 cells/well) and seeded
onto a 96-well ultra-low attachment plates. Samples were monitored for mammosphere
growth over 21 days, with media replaced periodically to account for nutrient depletion
and evaporation. Upon reaching endpoint, an inverted Olympus IX70 microscope was used
to image and analyze mammospheres. Criteria used to distinguish presence of
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mammosphere formation was based upon identification of clusters containing ≥ 5 cells.
Mammosphere formation efficiency was calculated by scoring each well for the presence
or absence of mammospheres (N=3), with subsequent analyses performed using L-Calc™
software (Stem Cell Technologies, Vancouver, BC).

Proteomic Analysis of Lung-CM
Proteomic analysis was carried out by Dr. Ying Xia in the Allan lab, in collaboration with
Dr. Gilles Lajoie (Department of Biochemistry). Lung-CM samples (N=3) were
concentrated and fractionated by 1D-SDS-PAGE followed by in-gel tryptic digestion
before injection into an Ultra-High Performance Liquid Chromatography instrument
interfaced with a LTQ Orbitrap Elite mass spectrometer (MS). Samples were scanned for
150 min using the data-dependent acquisition scan mode, selecting the 4 most abundant
ions from each survey for fragmentation and MS/MS detection, combined with iterative
exclusion (IE-MS) of previously scanned ions. Raw data was analyzed using “in-chorus”
protein identification methods employing X!Tandem, SpectraST, and PEAKS search
engines to allow comprehensive identification and increased statistical confidence in
independently identified proteins across different platforms. Classification analyses of
identified lung-CM proteins were performed using the PANTHER® Classification System
(Geneontology Consortium).

Statistical Analysis
All experiments were performed with at least three biological replicates (N=3), with
technical replicates (n=3) carried out internally for each biological replicate. Statistical
analyses were conducted using GraphPad Prism 6.0 (San Diego, CA, USA), with the
exception of the gene arrays analyzed with Qiagen’s online Data Analysis Center. Data
were presented as the mean ± standard error of the mean (SEM). A two-way analysis of
variance (ANOVA) was used to compare multiple means across different groups. Dunnet’s
post-hoc test was used to confirm significance. Values <0.05 were considered statistically
significant.
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5

RESULTS
Exposure to lung-conditioned media decreased ALDH activity
and CD44 expression in human breast cancer cells

Both the lung and bone have shown high susceptibility to the formation of secondary
tumours resulting from breast cancer metastasis52,56. Here, we analyze phenotypic
differences between two different human breast cancer cell lines, including the highly
metastatic SUM159 (HER2+) and the weakly metastatic MDA-MB-468 (TN) cell lines.
Assessment of phenotypic variation was assessed by flow cytometry analysis for ALDH
enzymatic activity and CD44 cell surface expression, producing the ALDH hiCD44+ stemlike cell phenotype. Contrary to our original hypothesis, 72-hour exposure to lung-CM
induced a significant decrease in the percentage of adherent cells with ALDHhi and/or
ALDHhiCD44+ phenotype in both MDA-MB-468 (4.4 ± 2.4%; 4.2 ± 2.1%) and SUM159
(9.2 ± 0.4%; 9.1 ± 0.4%) cell lines, relative to basal media controls (p<0.05) (Figure 6A
and B). SUM159 cells showed a significantly decreased ALDHhi and/or ALDHhiCD44+
phenotype after 72 hours BM-CM treatment (11.8 ± 0.8 %; 12.0 ± 0.9%) relative to basal
media controls (p<0.05) (Figure 6B). Further, lung-CM treatment significantly decreased
CD44 expression in both MDA-MB-468 and SUM159 cell lines (99.1 ± 0.2% and 71.2 ±
2.1%, respectively), relative to basal media controls (99.7 ± 0.1% and 99.9% ± 0.0%,
respectively) (p<0.05) (Figure 6A and B). BM-CM had no effect on CD44 expression in
either cell line.

Exposure to lung-conditioned media increased gene expression
of ALDH1A3 in human breast cancer cells
Next, we examined mRNA expression for ALDH1A1, ALDH1A3, and CD44 by RTqPCR. In contrast to the flow cytometry results for decreased CD44 expression and ALDH
activity, both MDA-MB-468 (Figure 7A) and SUM159 (Figure 7B) cell lines exposed to
lung-CM exhibited significantly increased CD44 (4.0 ± 1.1-fold [MDA-MB-468] and 1.8
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Figure 6. Exposure to lung-conditioned media decreased ALDH activity and CD44
expression in human breast cancer cells. (A) MDA-MB-468 and (B) SUM159 cells were
exposed to lung-conditioned media (lung-CM), bone marrow conditioned media (BMCM), or basal media (DMEM:F12 + Mito+) over 72 hours in culture (37°C, 5% CO2)
without media replacement. Adherent cells were harvested and analyzed by flow cytometry
for ALDH activity and CD44 expression, using the Aldefluor™ assay and CD44 antibody
respectively. Experiments were performed a minimum of three times and statistical
analyses were performed using one-way ANOVA and Dunnett’s post hoc test. Data is
presented as mean ± SEM. All significant values (*) are relative to the negative control
basal media treatment group (p<0.05, N=3).
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Figure 7. Exposure to lung-conditioned media increased CD44 and ALDH1A3 mRNA
expression in human breast cancer cells. (A) MDA-MB-468 and (B) SUM159 cells were
exposed to lung-conditioned media (lung-CM), bone marrow conditioned media (BMCM), or basal media for 24 hours in culture (37°C, 5% CO2) without media replacement.
Cells were harvested and RNA was analyzed by RT-qPCR to assess expression of CD44,
ALDH1A1 and ALDH1A3. All analyses were normalized to GAPDH expression and
shown as fold-changes relative to basal media (DMEM:F12 + Mito+) controls. Experiments
were performed a minimum of three times and statistical analyses were performed using
one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM. All
significant values (*) are relative to the negative basal media treatment group (p<0.05,
N=3).
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± 0.2-fold [SUM159]) mRNA expression compared to cells exposed to basal media
controls (p<0.05). Further, ALDH1A3 mRNA expression was significantly upregulated in
the SUM159 cell line following treatment with lung-CM (34.9 ± 13.6-fold), relative to
basal media control (p<0.05) (Figure 7B). Treatment with BM-CM did not lead to
significant changes in gene expression. Gene expression of ALDH1A1 was not
significantly affected by organ-CM treatments using either cell line. There was no
significant difference in relative CD44 mRNA expression levels between either adherent
or non-adherent MDA-MB-468 cell subpopulations, and the SUM159 cell line, in response
to basal media (Appendix 3). Moreover, the SUM159 cell line exhibited the lowest
ALDH1A1 and ALDH1A3 relative mRNA expression levels compared to both adherent
and non-adherent MDA-MB-468 cell subpopulations following basal media exposure
(p<0.05) (Appendix 3).

Treatment with lung-CM induced a viable, nonadherent breast cancer subpopulation
During the course of the phenotypic experiments, we observed that a subpopulation of nonadherent human breast cancer cells was produced following exposure to lung-CM, and to
a lesser extent following exposure to BM-CM. Using trypan blue exclusion (Figure 8A),
we quantified the production of non-adherent cells using four different human breast cancer
cell lines (MDA-MB-468, MDA-MB-231, MCF7, and SUM159). Surprisingly exposure
to lung-CM induced a viable non-adherent subpopulation when compared to basal and BMCM treatment. Moreover, we demonstrated that the ability of lung-CM to induce a viable
non-adherent subpopulation was cell line specific, where both of the less aggressive cell
lines (MCF7 and MDA-MB-468) demonstrated a viable non-adherent subpopulation in the
presence of lung-CM (10.8 ± 0.9% and 7.5 ± 0.6 % of whole population, respectively)
relative to basal media (0.3 ± 0.3% and 1.3 ± 0.3 % respectively) (p<0.05) (Figure 8B). In
contrast, the most aggressive SUM159 cells did not produce a non-adherent subpopulation,
irrespective of media conditions. Exposure to BM-CM or basal control did not result in a
prominent non-adherent subpopulation, however, viable non-adherent cells were
consistently produced among MCF7, MDA-MB-468, and MDA-MB-231 cells exposed to
BM-CM or basal media. Further analysis was performed using the LIVE/DEAD® assay to
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Figure 8. Exposure to lung-conditioned media supported the production of viable
non-adherent breast cancer cells assessed by trypan blue exclusion. MCF7, MDA-MB468, MDA-MB-231, and SUM159 human breast cancer cells were exposed to lung-CM,
BM-CM, and basal media for 48 hours in culture (37°C, 5% CO2) without media
replacement. Media was collected, centrifuged at 1000g for 5 minutes, and non-adherent
cells were manually counted using a hemocytometer to assess cell viability via trypan blue
exclusion. (A) Schematic of experimental approach. (B) Analysis of viable non-adherent
cells identified in MCF7, MDA-MB-468, MDA-MB-231, and SUM159 human breast
cancer cells following 48-hour exposure to lung-CM, BM-CM, or basal media.
Experiments were performed a minimum of 3 times and statistical analyses were performed
using one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM.
All significant values (*) are relative to the negative control basal media treatment group
(p<0.05, N=3).
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quantify viability based on a more sensitive fluorometric approach. Based on trypan blue
exclusion findings, MCF7 and MDA-MB-468 cell lines were chosen as candidates for
further analysis. Exposure to lung-CM significantly increased the percentage of viable,
non-adherent cells produced by both MCF7 and MDA-MB-468 cell lines (11.5 ± 1.2 %
and 34.9 ± 1.9 % respectively), relative to basal media control (p<0.05) (Figure 9A).
Further, treatment with BM-CM significantly decreased the viable non-adherent
subpopulation produced by the MCF7 cell line, but not the MDA-MB-468 cell line. (5.3 ±
0.1% and 8.8 ± 0.2 % respectively) (p<0.05) (Figure 9A). Both viable and non-viable cells
were evident through fluorometric analyses (Figure 9B).
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Figure 9. Exposure to lung-conditioned media supported the production of viable
non-adherent breast cancer cells assessed by Live/Dead® assays. MCF7 and MDAMB-468 human breast cancer cells were exposed to lung-CM, BM-CM, or basal media for
48 hours without media replacement. Media was collected, centrifuged at 1000g for 5
minutes, and non-adherent cells were manually counted using a hemocytometer to assess
cell viability via the Live/Dead® cell viability assay as per the manufacturer’s instructions.
(A) Analysis of cell viability in non-adherent cells in MCF7 and MDA-MB-468 human
breast cancer cells following 48-hour exposure to lung-CM, BM-CM, and basal media. (B)
Representative images (10x magnification) used to carry out fluorometric analysis.
Experiments were performed a minimum of three times and statistical analyses were
performed using one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean
± SEM. All significant values (*) are relative to the negative control basal media treatment
group (p<0.05, N=3).
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Lung-CM and BM-CM reduced CD44 expression, ALDH activity,
and ALDH1A1 gene expression in non-adherent human breast
cancer cells.
Recent evidence suggests the emergence of cancer cell subpopulations with reduced
adhesive characteristics originating from traditionally adherent breast, ovarian, and colon
cancer cell lines express heightened tumourigenic capacity, both in vitro and in vivo140,141.
To assess whether there were differences in ALDH and/or CD44 phenotypes between
adherent and non-adherent breast cancer cell subpopulations, MDA-MB-468 cells were
cultured in lung-CM, BM-CM, or basal media for 72 hours, and the non-adherent and
adherent subpopulations were isolated and analyzed by flow cytometry and RT-qPCR.
Contrary to our expectations, flow cytometry (Figure 10A) revealed that exposure to lungCM significantly decreased ALDH activity and CD44 expression, alone or in combination,
within the non-adherent subset (57.7 ± 2.5 % [CD44], 6.0 ± 1.1 % [ALDH], and 5.1 ± 0.9
% [ALDHhiCD44+]) compared to the non-adherent cells exposed to basal media (86.2 ±
2.9 % [CD44], 28.2 ± 0.9 % [ALDH], 23.3 ± 1.5 % [ALDHhiCD44+]) (β; p<0.05)
Furthermore, this decrease in ALDH activity and CD44 expression, alone or in
combination, was also significantly reduced relative to the adherent population exposed to
basal control media (99.7 ± 0.1 % [CD44], 26.1 ± 1.6 % [ALDH], 27.6 ± 0.2 %
[ALDHhiCD44+]) (*; p<0.05). Moreover, CD44 expression was significantly decreased in
non-adherent cells (57.7 ± 2.5 %), compared to their adherent counterpart after exposure
to the same lung-CM (99.1 ± 0.2 %) (α; p<0.05). Treatment with BM-CM significantly
decreased CD44 expression in the non-adherent subpopulation (78.3 ± 2.5 %), relative to
the adherent counterpart receiving the same BM-CM treatment (99.7 ± 0.1 %) (p<0.05).
There was no effect on ALDH activity, or the ALDHhiCD44+population, after treatment
with BM-CM (Figure 10A).
To further investigate phenotypic differences between adherent and non-adherent
subpopulations after exposure to lung-CM or BM-CM, RT-qPCR analysis was performed
to assess ALDH1A1, ALDH1A3, and CD44 mRNA expression (Figure 10B). We
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Figure 10. Exposure to lung-conditioned media reduced CD44 expression, ALDH
activity, and ALDH1A1 gene expression in MDA-MB-468 human breast cancer cells.
The MDA-MB-468 human breast cancer cells were exposed to lung-CM, BM-CM, or basal
media (DMEM:F12) for (A) 72 hours or (B) 24 hours in culture (37°C, 5% CO2) without
media replacement. Non-adherent and adherent subpopulations were harvested and
analyzed by (A) flow cytometry or (B) RT-qPCR. Data are presented as mean ± SEM.
Experiments were performed a minimum of 3 times and statistical analyses were performed
using a 2-way ANOVA with Dunnett’s post hoc test. Significant values are relative to the
adherent (*), non-adherent (β) basal media treatment group, or the adherent subpopulation
of the respective treatment (α) (p<0.05, N=3).
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observed that ALDH1A1 mRNA expression was significantly decreased after 24-hour
exposure to both BM-CM or lung-CM (0.4 ± 0.1-fold and 0.5 ± 0.1-fold, respectively),
relative to basal media (0.8 ± 0.1-fold) (p<0.05). There was no significant difference in
ALDH1A3 and CD44 mRNA expression between the adherent and non-adherent
subpopulations exposed to the same organ-CM (Figure 10B).

Lung-conditioned media impaired mammosphere formation by
non-adherent human breast cancer cells.
To assess whether stem-like function was affected by lung-CM or BM-CM, both adherent
and non-adherent cell subpopulations were subjected to a limiting-dilution mammosphere
formation assay. This assay enables the cells either poised for mitotic division or already
dividing to form non-adherent clusters, using a variety of activated stem cell-associated
signaling pathways to do so. MDA-MB-468 and MCF7 cell lines were exposed to lungCM, BM-CM, or basal media for 72 hours, and the non-adherent and adherent
subpopulations were plated in limiting dilutions using the mammosphere assay and
cultured for 21 days. Interestingly, non-adherent MCF-7 and MDA-MB-468 cells were
incapable of forming mammospheres following exposure to lung-CM (0.0 ± 0.0 freq. and
0.0 ± 0.0 freq., respectively), relative to the non-adherent subpopulation receiving basal
treatment (0.008 ± 0.002 freq. and 0.001 ± 0.000 freq., respectively) (p<0.05) (Figure 11A
and B). Conversely, exposure to basal media or BM-CM supported mammosphere
formation by both cell lines, irrespective of cell subpopulation. Regarding the adherent
subpopulations, treatment with organ-CM did not significantly affect mammosphere
frequency in either MCF7 or MDA-MB-468 cell lines. Further, treatment with BM-CM
significantly decreased mammosphere frequency among only the non-adherent MCF7 cell
subpopulation (0.001 ± 0.000 freq.), relative to the non-adherent subpopulation receiving
basal treatment (0.008 ± 0.002 freq.) (p<0.05) (Figure 11A).

Exposure to lung-CM increased mRNA expression related to
migration and decreased mRNA expression of CSC markers.
Next, a discovery-based approach was employed to uncover genes affected by lung-CM
treatment relevant to human CSC function. Both non-adherent and adherent MDA-MB468 cell subpopulations were exposed to basal or lung-CM for 24 hours, followed by RT-
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Figure 11. Exposure to lung-conditioned media impaired mammosphere formation
by non-adherent human breast cancer cells. (A) MCF7 and (B) MDA-MB-468 human
breast cancer cells were exposed to lung-CM, BM-CM, and basal media over 72 hours in
culture (37°C, 5% CO2) without media replacement. Adherent and non-adherent cell
subpopulations were harvested and viable cells were subjected to a mammosphere
formation assay over 21 days in culture. Cells were seeded in serial limiting dilution
fashion onto 96-well ultra-low attachment plates. Mammosphere formation was assessed
based on the presence or absence of clusters containing ≥ 5 cells per well, followed by
mammosphere frequency calculated using L-Calc software. Representative images of
mammospheres formed, or, absence of mammosphere formation by adherent and nonadherent (C) MCF7 and (D) MDA-MB-468 cell subpopulations. All images were taken at
10X magnification using an inverted Olympus IX70 microscope. Experiments were
performed a minimum of 3 times and statistical analyses were performed using one-way
ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM. All significant
values (*) are relative to the respective basal media treatment in the adherent or
nonadherent subpopulation (p<0.05, N=3).
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qPCR analyses. We observed the expression of five genes of interest were affected by
treatment with lung-CM, relative to basal treatment, including C-X-C Motif Chemokine
Ligand 8 (CXCL8), Cluster of Differentiation 24 (CD24), Mucin 1 (MUC1), Ataxia
Telangiectasia Mutated (ATM), and WEE1 G2 Checkpoint Kinase (WEE1) (Figure 12,
Tables 3,4). Exposure to lung-CM in both adherent and non-adherent subpopulations
significantly increased gene expression of the metastasis/migration associated gene,
CXCL8 (19.0 ± 8.8-fold [adherent] and 3.6 ± 1.0-fold [non-adherent]), relative to the same
subpopulations exposed to basal media (p<0.05) (Figure 12)142. Average Ct values
between adherent and non-adherent MDA-MB-468 cell subpopulations following 24-hour
exposure to lung-CM or basal media are provided (Appendix 4).
Conversely, exposure to lung-CM consistently decreased gene expression of two CSC
markers, CD24 and MUC1, in both adherent and non-adherent subpopulations (-4.6 ± 0.7fold [adherent CD24] and -3.2 ± 0.3-fold [non-adherent CD24]; -2.9 ± 0.6-fold [adherent
MUC1] and -6.1 ± 0.9-fold [non-adherent MUC1]), as well as two genes related to tumour
signaling molecules, ATM and WEE1 (-3.5 ± 1.9 fold [adherent ATM] and -4.9 ± 0.3-fold
[non- adherent ATM]; -2.2 ± 0.2-fold [adherent WEE1] and -4.8 ± 0.7-fold [non-adherent
WEE1]), relative to the same subpopulations exposed to basal media ( p<0.05) (Figure
12)143-146.

Lung-CM contained proteins related to migration, adhesion, and
stemness
Finally, mass spectrometry analysis was performed to assess the protein content within
lung-CM (relative to basal media) in order to gain insight into which effectors may be
contributing to the observed phenotype and behavior of breast cancer cells. Overall, 1,721
unique proteins were found in lung-CM. Using the PANTHER® classification system,
lung-CM proteins were organized based on extracellular (13.4%) or intracellular (86.6%)
localization (Figure 13A). Among proteins related to the extracellular space, further
classification was performed to divide proteins based on association with the extracellular
region (7.4%), membrane-bound proteins (3.5%), cellular junctions (1.3%), and
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Figure 12. Exposure to lung-conditioned increased mRNA expression related to
migration and decreased mRNA expression of CSC markers. MDA-MB-468 human
breast cancer cells were exposed to basal media or lung-CM for 24 hours. Adherent and
non-adherent subpopulations were harvested and RNA was extracted for use with Human
Cancer Stem Cell RT2 Profiler PCR® arrays. (A) Adherent cells exposed to lung-CM versus
adherent cells exposed to basal media. (B) Non-adherent cells exposed to lung-CM versus
non-adherent cells exposed to basal media. (C) Non-adherent versus adherent cells exposed
to lung-CM. The listed genes exhibited a statistically significant and at least 2-fold change
following normalization to GAPDH (p<0.05, N=3). Analyses were performed using
Qiagen’s Data Analysis Center® software.
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Table
Table 3.
3. CXCL8, CD24, MUC1, ATM and WEE1 emerge as key genes affected by
lung-CM treatment. Gene expression analysis was acquired from RT-qPCR of Human
Cancer Stem Cell® gene arrays. Findings represent differences in gene expression (> 2fold) induced by treatment with lung-CM in either adherent or non-adherent
subpopulations, relative to basal treatment. Arrows reflect direction of gene expression
fold-change significance.

A = Adherent

NA = Non-adherent
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Table 4. Function of CXCL8, CD24, MUC1, ATM, and WEE1. Genes of interest
were chosen for further characterization based on response to lung-CM treatment,
irrespective of adherent or non-adherent cell subpopulation.
Classification

Gene of Interest

Migration/Metastasis

C-X-C Motif Chemokine Ligand 8
(CXCL8)

Cluster of Differentiation 24
(CD24)

CSC Markers

Mucin 1
(MUC1)

Ataxia Telangiectasia Mutated
(ATM)

Tumour Signaling Molecules:

Function

Encodes interleukin 8 (IL8) protein
expression. As a proinflammatory
chemokine, IL8 can induce chemotaxis
of immune-related cells to a target
site147,148.

CD24 encodes a glycoprotein that is
anchored via a glycosyl
phosphatidylinositol (GPI) link to the
cell surface. CD24 protein functions as a
cell adhesion molecule, and its loss is
associated with a stem-like cancer cell
phenotype62.

MUC1 encodes for cell surface
glycoprotein with an active extracellular
domain due to O-linked glycosylation.
The cytoplasmic tail of MUC1 functions
as an oncoprotein through interactions
with tumour promoting pathway and is
often overexpressed in certain cancers.
The protein can also localize to the
nucleus for interaction with WNT
signaling149.

ATM encodes for serine/threonine
kinase, which belongs to the PI3/PI4kinase family. Together with ATR, ATM
is considered a master regulator of cell
cycle checkpoints. ATM has a central
role in repair of double-stranded DNA
breaks150. Further, elevated ATM
expression has been associated with
favorable patient prognosis151.

Cell Cycle Control

WEE1

WEE1 encodes for a nuclear kinase that
is part of the Ser/Thr protein kinase
family. Through the inhibition of CDK1,
WEE1 is a negative regulator of entry
into mitosis (G2 – M)146. In cancer,
impaired WEE1 has led to the loss of
DNA-damage induced apoptosis and
aberrant mitosis146.
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A

B

Figure 13. Classification of intra- and extracellular proteins found in lung-CM. Mass
spectrometry analysis (N=3) revealed 1,721 proteins that are unique to the lung-CM
relative to basal media. (A) Among these proteins, 13.4% are classified as extracellular and
86.6% are classified as intracellular compartmentalized proteins. (B) Proteins belonging to
the extracellular compartment are of particular interest as they may be secreted from the
lung as soluble proteins and impose an effect on human breast cancer cells. Among the
proteins belonging to the extracellular compartment, further classification associated these
proteins with the extracellular region (7.4%), membrane-bound (3.5%), cellular junctions
(1.3%), and extracellular matrix (1.2%). Analyses were performed using PANTHER®
Classification System software.
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extracellular matrix (1.2%) (Figure 13B). From the soluble extracellular compartment,
osteopontin (OPN), periostin (POSTN), a disintegrin and metalloproteinase domaincontaining protein 10 (ADAM10), and β-catenin were of particular interest as they have
strong associations with cell migration and adhesion pathways136,152-154. Upon analysis of
the intracellular compartment, several proteins associated with angiogenic VEGF,
stemness (WNT/NOTCH), and migratory (Ras/Rho) pathways were observed to be
present155-157. When assessing proteins related to CD44, ADAM10 was present in the lungCM, and absent in the basal media (Table 5, Figure 14A)152. Among intracellular proteins,
6 proteins were found to be related ALDH/RA signaling pathway (Table 5) including
retinol binding protein 1 (RBP1), alcohol dehydrogenase 1 (ADH1), aldehyde
dehydrogenase 1A1 and 1A7 (ALDH1A1 and ALDH1A7), cytosolic retinoic acid binding
protein 2 (CRABP2) and fatty acid binding protein 5 (FABP5) (Figure 14B)158,159.
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Table 5. Function of proteins within lung-CM related to ALDH/RA signaling
pathway and CD44 cleavage.
Potential Interaction with:

Proteins of Interest

Retinol Binding Protein 1
(RBP1, CRBP1)

Retinol Binding Protein 4
(RBP4)

Alcohol Dehydrogenase 1
(ADH1)

Aldehyde Dehydrogenase 1A1

ALDH/RA

(ALDH1A1)

Function

Involved in retinol transport once the
vitamin A alcohol has entered the cell
(functions intracellularly)160.

Major role in retrieving retinol from liver
storage, and transporting to peripheral
tissue through systemic circulation
(functions within blood plasma)161.

Enzyme involved in oxidation of retinol
to retinal, an aldehyde. Required for
clearance of excess retinol, which could
result in retinol toxicity162.

Enzyme responsible for the further
oxidation of retinal to retinoic acid (RA).
Enzyme activity has significant
implications regarding tumour
development and stem cell
maintenance92.

Pathway
Aldehyde Dehydrogenase 1A7
(ALDH1A7)

Cytosolic Retinoic Acid Binding
Protein 2

Binds to, and translocates RA into the
nucleus for activation of RAR/RXR
transcription machinery159.

(CRABP2)

Has anticarcinogenic effects associated
with cell apoptosis, differentiation, and
growth arrest159.

Fatty Acid Binding Protein 5

Can also bind to RA and translocate into
the nucleus for activation of PPAR
pathway159.

(FABP5)

CD44 Cell Surface Expression

ALDH1 family isoenzyme involved in
RA synthesis. Has been associated with
olfactory and respiratory tissues163.

Disintegrin and Metalloproteinase
Domain-containing Protein 10
(ADAM10)

Has procarcinogenic effects associated
with cell survival and proliferation159.

ADAM10 is a proteolytic enzyme that is
capable of preferentially cleaving
CD44152.
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Figure 14. Mass spectrometry analysis of lung-CM identifies key proteins related to
the ALDH/RA and CD44 pathways. Mass spectrometry analysis was carried out to
investigate proteins contained with the lung-conditioned media and their potential
relationship with the phenotypic and functional behavior of breast cancer cells. (A) The
CD44-related disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)
cleaves CD44 at the extracellular ectodomain. (B) Several proteins relevant to the
ALDH/RA pathway (labelled in red) were found to be present within the lung-CM. Those
proteins included: retinol binding protein 1 and 4 (RBP 1 + 4), alcohol dehydrogenase 1
(ADH 1), aldehyde dehydrogenase 1A1 and 1A7 (ALDH1A1 and ALDH1A7), cytosolic
retinoic acid binding protein 2 (CRABP2), and fatty acid binding protein 5 (FABP5). There
may be a potential mechanism for these soluble proteins to be internalized by cancer cells
and utilized as exogenous machinery.
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6

DISCUSSION

Among Canadians, the mortality rate associated with breast cancer has declined by 44%
since its peak in 19861. Such a drastic decrease can be attributed to improved early-stage
tumour detection, by government-funded mammography screenings, made readily
available to Canadians in 1992164. Although mortality rates have decreased, the incidence
rates have not decreased. Since 1988, the age-standardized incidence rates have remained
high among women and seen little change in this trend as of late1. This stagnant incidence
rate has maintained breast cancer’s position as the third most common cancer among
Canadians, making up 13% of all cancers and 25% of cancers in women1. What is more
dismal, after receiving adjuvant chemotherapy for the primary tumour, patients who
developed metastatic disease within 10 years of treatment were met with a near
unanimously fatal outcome, a statistic that has not changed in the last 30 years165.

Breast cancer is currently a treatable disease, but a lack of effective therapies in the
metastatic setting render breast cancer largely incurable once the cancer has disseminated
beyond the breast. This is due in part to tumour heterogeneity which has presented a major
obstacle for the research and clinical communities, making cancer biology complex and a
generic treatment regimen difficult to achieve166. For patients with endocrine-responsive
tumours, hormonal therapy has demonstrated modest improvements in overall patient
survival167. When endocrine-receptors are absent, hormonal therapy becomes ineffective,
and systemic chemotherapy is necessary to target a wide range of rapidly proliferating cell
types167. Often, tumourigenic cells acquire resistance to primary treatment strategies and
become resistant to therapy, allowing the metastatic processes to persist166,167. The issue
concerning current therapies is that they do not eradicate all cancer cells within a patient,
neglecting cells that may exhibit a decreased rate of proliferation. The emerging CSC
model suggests that a rare population of slow-proliferating, tumourigenic cells are capable
of repopulating a heterogeneous tumour and contribute to disease recurrence and evasion
of conventional therapies168. Several studies have identified subpopulations of potential
stem-like cancer cells using traditional stem cell markers, such as ALDH, alone or in
combination with different intrinsic and extrinsic factors. In breast cancer, stem-like cells
have been phenotypically identified as having high enzymatic ALDH activity and CD44
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cell surface expression, however targeted treatments have been unsuccessful due the
transient and dynamic phenotype of stem-like cancer cells61,62,169. Understanding the role
of stem-like and/or metastasis-initiating cancer cells during tumour progression and/or
metastatic development is critical for establishing effective treatment strategies to target
these rare and aggressive populations.

The significance of CSCs in breast cancer metastasis and secondary tumour formation is
important to consider in the context of preferential patterns of organ tropism. Massagué
and colleagues contributed significantly to knowledge about organ-specific breast cancer
metastasis when they observed that intrinsic genes within breast cancer cells can mediate
metastasis to the lung, bone marrow, and brain47-49. Although profound, these findings did
not address the role of the organ microenvironment, nor the role of CSCs in organ tropism
of breast cancer metastasis. Efforts in our laboratory aimed to address these voids by
demonstrating the potential for soluble proteins generated by the lung and BM
microenvironments to promote migratory and proliferative behaviour in stem-like
ALDHhiCD44+ breast cancer cells in vitro, and increased incidence of spontaneous
metastasis of these stem-like cells to lung in vivo

52,70,136

. These initial investigations

suggested a role for the lung and bone marrow microenvironments in supporting growth,
migration and metastasis of ALDHhiCD44+ breast cancer cells. However, it was unclear
whether the lung and/or bone microenvironments could additionally promote the
acquisition of a stem-like phenotype and function within breast cancer cell populations,
and this thesis focused on this question. We utilized an ex vivo model of lung- and boneconditioned media and hypothesized that exposure to these lung or bone
“microenvironments” would increase the proportion of breast cancer cells expressing the
stem-like ALDHhiCD44+ phenotype and enhance stem-like cell behaviour.

Summary of Key Experimental Findings
The key experimental findings of this thesis are summarized in Table 6 and listed below.
1. Exposure to lung-CM decreased the frequency of MDA-MB-468 and SUM159
breast cancer cells expressing the stem-like ALDHhiCD44+ phenotype.
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2. Exposure to lung-CM increased the frequency of a viable, non-adherent
subpopulation in MDA-MB-468 and MCF7 human breast cancer cells.
3. Exposure to lung-CM decreased CD44 expression in non-adherent MDA-MB-468
human breast cancer cells.
4. Exposure to lung-CM impaired mammosphere formation by non-adherent MDAMB-468 and MCF7 human breast cancer cells.
5. Lung-CM contained proteins related to migration, adhesion, and stemness.
6. Exposure to lung-CM resulted in increased mRNA expression related to migration
and decreased mRNA expression of “cancer stem cell (CSC)” markers.

Table 6. Summary of results assessing adherent and non-adherent cell subpopulations
treated with BM-CM or lung-CM.
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Lung-CM inhibits stem-like phenotype and behaviour in
adherent human breast cancer cells
Contrary to expectations, we observed that exposure of MDA-MB-468 and SUM159 breast
cancer cells to lung-CM decreased the proportion of cells expressing an ALDHHiCD44+
phenotype. Of the parameters that comprise our chosen stem-like phenotype, ALDH
activity was significantly decreased in response to lung-CM treatment in both cell lines,
while CD44 expression was only decreased in the SUM159 cell line. Treatment with BMCM also decreased the ALDHHiCD44+ phenotype, however, this decrease was modest in
comparison to lung-CM. This discovery was unanticipated given that lung and BM tissue
are highly targeted sites of metastasis, together with accumulating evidence suggesting that
ALDHhiCD44+ cells play a key role in driving breast cancer progression52,72,170,171.
To further investigate the influence of lung-CM, we performed mRNA analysis of CD44,
and two major ALDH isoenzymes, ALDH1A1 and ALDH1A372. Due to the inherent delay
associated with gene transcription prior to achieving functional protein, RT-qPCR analysis
was performed after 24-hour exposure to organ-CM. Interestingly, mRNA transcription
analyses demonstrated a significant upregulation of CD44 mRNA expression after 24-hour
treatment with lung-CM, in both MDA-MB-468 and SUM159 cell lines. This increase in
CD44 mRNA expression was not consistent with our flow cytometry results measuring
decreased CD44 cell surface expression. This is not surprising as CD44 cleavage often
occurs at the cell surface during locomotion and migration, suggesting a potential positive
feedback system driving CD44 mRNA expression following treatment with lung-CM.172
Further, ALDH1A3 mRNA expression was also increased following treatment with lungCM in the SUM159 cell line only. As ALDH activity was largely decreased by lung-CM
treatment following flow cytometry analysis, this warranted further investigation to
measure ALDH protein level. However, western blot analysis of ALDH1A3 protein did
not indicate a significant difference in protein levels between basal media and lung-CM
treatments, suggesting potential post-transcriptional or post-translational modifications
that may interrupt the production of functional ALDH1A3 enzyme (Appendix 2). In the
future, further analysis of terminal protein localization and the extent of ubiquitination on
the ALDH1A3 protein may help better understand the opposing data (e.g. whether proteins

64

are destined for lysosomal degradation)173. Another factor that may contribute to a loss of
ALDH activity is stem cell differentiation or maturation. Although high ALDH activity is
associated with the detection of a stem-like phenotype, ALDH can induce differentiation
through the production of RA and subsequent downstream signaling pathways. Therefore,
treatment with lung-CM could induce stem-like cells to differentiate, resulting in decreased
ALDH activity. In a recent study, Muramoto et al found that inhibition of the ALDH1
enzyme impeded the differentiation of murine hematopoietic stem cells (HSCs), resulting
in a 9-fold expansion of radioprotective cells174. These HSCs both maintained their stemlike state and maintained radioprotection through inhibition of ALDH activity. Another
study performed by Hessman et al demonstrated that decreased ALDH1 protein expression
in primary and metastatic colorectal cancer samples correlated with advanced and
metastatic cancers, while high ALDH1 expression was associated with non-metastatic
tumours175. Together with findings in the literature, our recent data suggests a loss of stemlike phenotype could result in increased metastatic capacity.
In addition to phenotypic analysis by flow cytometry, the enrichment of stem-like cells
through spheroid formation has become a useful technique to measure stem-like behavior
of cancer cell populations. Introduced in 1992 by Reynolds and Weiss to assess
proliferation, self-renewal, and multipotency of neural precursor cells, the neurosphere
assay has since been repurposed for use in a variety of models, particularly CSC biology176.
Adapted by Dontu and colleagues, the mammosphere assay utilizes non-adherent and nondifferentiating culture conditions to evaluate individual breast cancer cells on their ability
to self-renew/proliferate in suspension, forming multicellular mammospheres in vitro177.
In the current study, we set out to investigate the mammosphere-forming capacity of
adherent MCF7 and MDA-MB-468 human breast cancer cells after exposure to lung- or
BM-CM. We did not observe a significant effect on mammosphere formation frequency in
either adherent MCF7 or MDA-MB-468 cells following exposure to lung-CM or BM-CM.
Both cell lines were capable of forming mammospheres irrespective or organ-CM received,
suggesting that factors within the lung-CM or BM-CM did not interfere with stem-like
functions such as mammosphere formation among the adherent cell subpopulation.
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Taken together, exposure to lung-CM decreased the proportion of cells expressing the
stem-like ALDHhiCD44+ phenotype, however did not affect functional stem-like behaviour
of human breast cancer cells. This suggests that the lung microenvironment does not
promote stem-like phenotype in adherent breast cancer cells, and instead, may inhibit it.

Lung-CM induced a viable, non-adherent breast cancer cell
subpopulation with decreased stem-like phenotype and function
During the course of our studies, we qualitatively observed that exposure to lung-CM
induced a non-adherent breast cancer cell subpopulation. Both the MDA-MB-468 and
SUM159 cell lines have been characterized as adherent in culture, leaving the possibility
of a thriving non-adherent subpopulation among these cells unlikely178,179. Interestingly,
upon trypan exclusion analysis, a viable, non-adherent MDA-MB-468 subpopulation was
confirmed after exposure to lung-CM. This finding was not nearly as pronounced after
either BM-CM or basal control treatments, and completely absent in the more metastatic
SUM159 cell line, irrespective of organ-CM. Since only the MDA-MB-468 cell line
produced a non-adherent subpopulation, we performed a screening of two additional
human breast cancer cell lines, MDA-MB-231 and MCF7, to assess if other traditionally
adherent cell lines would generate a similar non-adherent subpopulation following
exposure to lung-CM. Both additional cell lines produced a non-adherent subpopulation,
however of the four cell lines tested, the least aggressive MCF7 and MDA-MB-468 cell
lines most efficiently produced viable, non-adherent cells. We next performed a
LIVE/DEAD® viability assay on the two candidate cell lines, MDA-MB-468 and MCF7 to
confirm our trypan exclusion results. Upon fluorometric analysis, both MDA-MB-468 and
MCF7 cells demonstrated a significant increase in viable, non-adherent cells after lungCM treatment. The observation that the induction of viable non-adherent cells was most
pronounced after treatment with lung-CM suggests that components of the lung
microenvironment may interact with adherent breast cancer cells in a manner that induces
cell detachment.
To accurately compare differences between the stem-like phenotype of adherent and nonadherent breast cancer cell subpopulations, we performed additional flow cytometry
analyses to assess ALDH activity and CD44 cell surface expression after treatment with

66

organ-CM. Again unexpectedly, we observed that exposure of the non-adherent MDAMB-468 cell subpopulation to lung-CM further decreased CD44 expression relative to the
adherent subpopulation, while ALDH activity, and the proportion of cells expressing the
stem-like ALDHhiCD44+ phenotype, remained relatively low and unchanged between both
adherent and non-adherent subpopulations. When comparing BM-CM treatment between
adherent and non-adherent MDA-MB-468 cells, we also observed a decrease in CD44
expression within the non-adherent subpopulation, yet this decrease was limited in
comparison to the lung-CM response. Consistent with our analyses of protein expression,
gene expression analysis revealed that ALDH1A1 gene expression in the non-adherent
MDA-MB-468 subpopulation was significantly downregulated after exposure to both
lung- and BM-CM. Thus, while the proportion of non-adherent and adherent cells
expressing the stem-like ALDHHiCD44+ phenotype was largely unaffected, CD44
expression was consistently decreased in the non-adherent cell subpopulation relative to
the adherent counterpart, especially after treatment with lung-CM. In a recent study by
Ngan et al, loss of E-cadherin and CD44 expression were significantly correlated with poor
survival in colorectal cancer patients180. In addition, a study conducted by Sugino et al
demonstrates that a loss in CD44 expression resulted in tumour cell detachment from the
basal membrane, and subsequent invasion by cancer cells181.
Next, we wanted to address potential differences in stem-like function between nonadherent and adherent breast cancer cell subpopulations after exposure to organ-CM.
Research published by House et al demonstrated a non-adherent subpopulation in both
ACI-23 and OVCAR-5 human ovarian cancer cell lines that more readily produce
spheroids in vitro, and larger tumours in vivo140. Furthermore, a Morata-Tarifa et al found
trypsin sensitive (non-adherent) human breast and colon cancer cells demonstrated
increased sphere-forming capacity in vitro, when compared to their trypsin-resistant
(highly adherent) counterparts141. We performed a similar experiment whereby we exposed
adherent and non-adherent subpopulations of both MDA-MB-468 and MCF7 breast cancer
cells to organ-CM, and subjected them to the mammosphere formation assay in limiting
dilutions. Contrary to the findings of House et al Morata-Tarifa et al, our data does not
demonstrate increased mammosphere formation by non-adherent cells. Instead, we
observed that treatment with lung-CM significantly impaired mammosphere formation in
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both cell lines, while treatment with BM-CM decreased mammosphere formation in nonadherent MCF7 cells. Interestingly, both MCF7 and MDA-MB-468 non-adherent cell
subpopulations exposed to lung-CM were incapable of forming mammospheres after 21
days in culture. As a cell adhesion molecule, CD44 expression is significant in making
cell-cell and cell-ECM interactions. Ponti et al demonstrated the necessity for CD44
expression in successful mammosphere formation when they documented 95-96% of cells
within mammospheres derived from MCF7 and three primary cells lines were
CD44+/CD24-182. Their findings suggest that the inability of our non-adherent breast cancer
cells to form mammospheres could be attributed to the observed loss of cell surface CD44
expression. Taken together with our previous studies and our observations here that the
non-adherent breast cancer subpopulation was less stem-like than the adherent
subpopulation in the presence of lung-CM, our findings suggest that while CD44 and
stemness are likely important for the earlier steps of metastasis, they may not be necessary
once breast cancer cells become established in the lung microenvironment52,70.

Lung-CM contained proteins related to migration, adhesion, and
stemness
Distant metastases account for nearly 90% of cancer-related deaths, yet the processes
leading to the development of distant tumours is the most poorly understood aspect of
cancer pathogenesis183,184. Accumulating data now suggests that breast cancer, leukemia,
sarcoma, and kidney cancer have a preferential pattern of metastasis towards the lung
tissue, while other cancers affecting the colon, head-and-neck, and pancreas also reach the
lungs, but in a non-specific manner118,185. The lung microenvironment is composed of
insoluble and soluble components, both of which have unique roles in tumourigenesis. The
insoluble lung microenvironment is composed of several structural ECM proteins such as
collagens, elastin, fibronectin, laminin, and proteoglycans that together, represent nearly
65% of the lung tissue186-188. The majority of tissue infrastructure in the lung is provided
by these ECM components, and often commandeered by tumour cells as the porous and
elastic environment is well suited for metastatic colonization189-191. Similar to the insoluble
lung microenvironment, ECM components such as collagens, fibronectins, and laminins
are present in varying levels within the insoluble structures of cancellous bone
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matrices192,193. Considering these similarities, investigation of the soluble lung
microenvironment could provide insight relative to the insoluble component. Composed of
more than 60 cell types, a variety of unique secretions are produced by cells of the lung
which may have a pivotal role in mediating preferential metastases194. Findings by Chu et
al and Pio et al demonstrated that soluble proteins within the lung and BM
microenvironments induced preferential migration in a chemotactic manner. In particular,
both studies noted an increased migratory capacity among the stem-like ALDHhiCD44+
breast cancer cell population towards both lung and BM microenvironments, supporting
Croker et al finding of increased spontaneous metastases by ALDHhiCD44+ breast cancer
cells to the lung in vivo52,70,136. To begin to uncover potential mechanisms that may be
involved in preferential metastases to the lungs, our goal was to start to investigate the
composition of lung-CM and assess how this may be influencing stem-like phenotype and
characteristics of human breast cancer cells.
Investigation of our lung-CM treatment was initiated by Chu et al. through protein array
analysis. Over 70 unique proteins were observed in the lung-CM that have an association
with migration, proliferation, adhesion, and metastasis52. Much of this work highlighted
the role of the lung microenvironment as a chemoattractant, where OPN was suggested to
have significant roles in breast cancer migration towards the lungs52. To provide a more
unbiased analysis of the composition of lung-CM, we utilized mass spectrometry and found
a total of 1,721 soluble proteins unique to the lung-CM, that were absent in the basal
treatment. The clear majority, 86.6%, were intracellular-derived proteins, likely originated
from the lung tissue as an artifact of the dissociation process required to cultivate lungCM. The remaining 13.4% of proteins belong to the extracellular compartment, making
this proportion of proteins a key area for investigation. As our treatment conditions
required human breast cancer cells to be cultured with organ-CM, proteins that would
normally be associated with the extracellular space in vivo are prone to interact with seeded
breast cancer cells in vitro. Among the proteins identified, key mediators of migration and
adhesion including OPN, POSTN, ADAM10, and β-catenin were present.
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Osteopontin
Confirming findings by Chu et al, lung-derived OPN was present in the lung-CM and has
been previously been implicated in cell-matrix interactions that promote cell motility,
invasion, and angiogenesis195-197. Using a melanoma model, Kumar et al found the
knockout of OPN in mice decreased tumour growth, impaired angiogenic processes, and
stunted metastatic potential195. Findings by Pio et al also support the importance of BMderived OPN in promoting breast cancer cell migration and mammosphere formation in
vitro among whole cell and stem-like ALDHhiCD44+CD24- breast cancer cell
populations136. Moreover, experiments involving exogenous overexpression of OPN have
demonstrated its role as a negative regulator of HSC self-renewal and localization within
BM, while OPN-null mice displayed a clear expansion of the HSC population in murine
BM130,198. With lung-derived OPN present within lung-CM, the negative regulation of HSC
maintenance by OPN suggests this function could potentially extend to CSC regulation,
inhibiting expansion of stem-like cells when OPN is present within the microenvironment.
Thus, OPN’s association with metastatic processes and regulation of stem cell fate may
contribute to the reduction in ALDHHiCD44+ phenotype and stem-like function
demonstrated in our study.

Periostin
With implications in tumourigenesis, the identification of POSTN within lung-CM is also
an interesting finding as its secretion has been found to originate from both tissue stromal
cells and infiltrating cancer cells120. Abnormally high levels of POSTN have been reported
both experimentally and clinically in various cancers of the breast, ovary, and liver199,200.
In the pulmonary tissue, lung fibroblasts secrete POSTN into the extracellular space to
transmit signals from the ECM to cells via interactions with surface receptors such as
integrins, mediating cell motility, adhesion, and proliferation201. It is well documented that
POSTN promotes tumour cell invasion and metastasis through the integrin/PI3/AKT
pathway, promoting the development of various cancers153,202. In particular, POSTN
interaction with integrin αvβ3 expressed on the endothelium of alveolar micro-vessels cells
has been shown to mediate fibroblast or malignant cell migration203,204. Sasaki et al utilized
in situ RNA hybridization to identify high POSTN gene expression was not occurring from
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within the breast cancer cells, but instead originating from stromal cells directly adjacent
to the bulk tumour205. Although many studies postulate the source of POSTN being the
cancer cell, very few cancer cell lines have demonstrated significant POSTN mRNA levels
in vitro, suggesting that stroma-derived POSTN may be of interest during
tumourigenesis206. The finding that lung-CM contains POSTN derived from the pulmonary
stroma suggests that its presence could be a factor that promotes metastasis and suppresses
stem-like characteristics.

β-Catenin
The presence of β-catenin within the lung-CM is worthy of further investigation as it has
been implicated as a factor involved in determining stem cell fate207,208. Regulated by
extracellular Wnt ligand interactions with the Frizzled receptor family, the canonical
Wnt/β-catenin signaling pathway allows for the intracellular accumulation of β-catenin
resulting in induction of stem cell differentiation209. Aberrant fluctuation of cytosolic βcatenin has been associated with malignancy in various organs, and several studies report
that basal-type TN breast cancers expressing unusually high levels of β-catenin have worse
overall survival154,210,211. Although its production occurs intracellularly, recent findings
have demonstrated that β-catenin can be packaged in exosome-like vesicles and transported
into the extracellular space or circulation212,213. Further, Dovrat et al demonstrated that
human embryonic kidney cells (HEK293) not only produced extracellular vesicles
containing β-catenin, but that these vesicles were prooncogenic as the adjacent target cells
receiving the exosome translocate β-catenin to the host nucleus and activates Wntstimulated transcription212. Since our model of the lung microenvironment involves
mechanical dissociation of murine lung tissue, if exosomal structures containing β-catenin
had formed, such a vesicle could be lysed and its contents released into the lung-CM for
interaction with human breast cancer cells in vitro. Thus, potential uptake of β-catenin by
human breast cancer cells could lead to accumulation within the cell, activating canonical
Wnt signaling to induce differentiation among CSCs, resulting in a decreased stem-like
ALDHhiCD44+ phenotype.
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Proteins that Influence Cell Detachment and Extracellular
Transport
To address the potential role of the lung microenvironment in mediating the transition of
adherent human breast cancer cells into a non-adherent subpopulation, both β-catenin and
ADAM10 have demonstrated mechanisms involved in cellular detachment. With the
possibility that β-catenin internalization by breast cancer cells could have potentially
occurred in our ex vivo model, previous studies have shown that β-catenin overexpression
in Madin-Darby Canine Kidney (MDCK) cells induced a transformation of these
traditionally highly adherent epithelial cells towards a mesenchymal phenotype with
distinct cellular extensions214. Furthermore, several studies have confirmed that MDCK
cell survival is anchorage-dependent, however Orford et al demonstrate that
overexpression of β-catenin resulted in 75% of transfected MDCK cells to maintain
viability in suspension for at least 16 hours, avoiding cell death by anoikis214,215. These
findings support a potential mechanism whereby exogenous β-catenin uptake could induce
an epithelial-to-mesenchymal transition that promotes anchorage-independent survival of
single cells.

Likewise, when considering the role of ADAM10 in promoting anchorage-independence,
several studies have reported the ADAM family of proteases to cleave the extracellular
domains of transmembrane proteins. In particular, ADAM10 specifically cleaves CD44 at
the ectodomain in order to direct cell migration152. As a cell adhesion molecule, CD44
expression plays an important role in cell-cell and cell-ECM interactions216. Perhaps the
initial induction of a non-adherent breast cancer cell subpopulation and the inability of
these cells to form mammospheres after exposure to lung-CM could be attributed, at least
in part, to the loss of cell surface CD44 expression via ADAM10 cleavage. In a recent
study performed by Mullooly et al, inhibition of ADAM10 with small interfering RNA
(siRNA) resulted in significantly decreased invasion and migration of MDA-MB-231
human breast cancer cells in vitro217. Moreover, using 117 primary tumour extracts they
demonstrated that elevated ADAM10 protein expression correlates with high-grade,
aggressive breast tumours217. Their results suggest that in the absence of ADAM10, CD44
mediated cell-cell and cell-ECM interactions remain intact, resulting in a decrease in
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migratory and invasive capacity of human breast cancer cells. In addition, a mechanistic
model of cell motility proposed by Nagano et al highlights the importance of ADAM10
after its activation by stretch-activated calcium ion (Ca2+) channels that promptly result in
the cleavage of CD44 at the trailing end of the cell172. Taken together, both β-catenin and
ADAM10 have previously been shown to promote cellular detachment and anchorageindependent growth. As both proteins are soluble, can exist in the extracellular space, and
are present within our lung-CM model, potentially one or both proteins may be involved
in the induction of the observed non-adherent breast cancer subpopulation.

Potential Influence of Intracellular Proteins
Lastly, considering that potential mechanisms exist allowing intracellular proteins to be
packaged and exported from the cell in the form of exosomal vesicles, it is important to
consider what implications this may pose for proteins that are exclusive to the intracellular
space. Among the intracellular proteins that made up 86.6% of the proteins detected in the
lung-CM, six proteins overlap with key regulators of the ALDH/RA signaling pathway.
These proteins include: RBP1, ADH1, ALDH1A1, ALDH1A7, CRABP2, and FABP5. As
previously discussed, it is not uncommon for cells to internalize and utilize proteins from
the extracellular microenvironment. By expressing an endogenous ligand that mimics
endocytic criteria for the receptor of interest, small molecules and proteins can be
internalized into the cell218. In a groundbreaking discovery led by Sansone and colleagues,
the horizontal transfer of the entire mitochondrial genome was packaged and transported
to neighboring cells via extracellular vesicles219. Further, they determined that primary
breast cancer samples from patients receiving hormonal therapy were deficient in oxidative
phosphorylation, and that murine-derived mitochondrial DNA (mtDNA) packaged into
extracellular vesicles successfully restored metabolic function in these cancer cells,
inducing their exit from a dormant state219. Moreover, they demonstrated that this
phenomenon also exists in stem-like cancer cells, as mutated mtDNA transfer from
hormone therapy resistant cells into hormone therapy sensitive cells resulted in elevated
self-renewal capacity219. Whether this mechanism of internalization is feasible with respect
to ALDH/RA components in our model system, and if so, would render functional proteins
has yet to be investigated.
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Overall, the lung microenvironment is an abundant source of exogenous proteins that
influence human breast cancer cell function. In the current study, we have identified several
intra- and extracellular soluble proteins within lung-CM such as OPN, POSTN, β-catenin,
and ADAM10 that may have specific roles in propagating cell migration, detachment from
a monolayer, anchorage-independent growth, and differentiation. Interestingly, some of
these exogenous proteins have been implicated in reducing stem-like phenotype and
behaviour in experimental models, findings that are in keeping with our results. In addition,
we have highlighted potential internalization mechanisms that could potentiate the
packaging of intracellular machinery into extracellular vesicles for successful delivery into
a recipient cell.

Lung-CM increases gene expression related to
migration and decreases expression of CSC markers
The stochastic model of cancer development speculates that the accumulation of random
pro-oncogenic mutations within a cell is the source for aberrant growth patterns and
subsequent formation of homogenous tumours220. Consequently, the approach to cancer
therapy has remained relatively archaic, utilizing cytotoxic agents as a means for targeting
a group of homogenous, highly proliferative cells, without discriminating between healthy
and malignant cells221. Systemic chemotherapy is highly efficient at inducing apoptosis in
cells that are actively undergoing mitosis, but ineffective at targeting quiescent cells that
are arrested in G0-G1 phase of the cell cycle221. Despite the phenotypic heterogeneity of
tumour cells documented since the earliest days of cancer cell biology, the concept of intratumour heterogeneity has gained very little traction until recently222,223. Mounting evidence
suggests that a bulk tumour is far from homogenous, and instead, is composed of a myriad
of distinct cell types that coordinate with each other to maintain tumour homeostasis and
drive tumour development224. The emerging hierarchical CSC hypothesis has received a
lot of attention as it challenges the stochastic model and provides a viable explanation for
intra-tumour heterogeneity. The first studies to support the CSC model of cancer
development in solid tumours was performed by Al-Hajj and colleagues when they
successfully isolated a population of stem-like CD44+CD24- breast cancer cells that could
recapitulate a breast tumour in 8 of 9 mice tested62. As few as 100 stem-like CD44+CD24-
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breast cancer cells could reconstitute a tumour, while significantly higher numbers of nonstem-like breast cancer cells were incapable of tumour formation62. Since its introduction,
several studies have reported an association with the hematopoietic stem cell marker,
ALDH, and its relation to the CSC model. In particular, ALDH activity in tumour cells has
been demonstrated experimentally both in vitro and in vivo to increase invasive potential,
migratory capacity, chemoprotection, and self-renewal in various types of solid
tumours61,70,76,171,225,226.
Clinically, breast cancer dissemination has been well documented to metastasize in an
organ-specific pattern, often targeting the lung, BM, liver, brain and lymph nodes. Chu et
al brought to light the importance of the soluble organ microenvironment, as they
demonstrated that lung and BM microenvironments were especially capable of promoting
migration of stem-like ALDHHiCD44+ breast cancer cell phenotype in vitro52. Research by
Croker et al lent support to these findings as they reported increased incidence of
spontaneous lung metastases by stem-like ALDHHiCD44+ breast cancer cells in vivo70.
Together, work conducted by Chu et al and Croker et al suggest that the lung
microenvironment supports the metastasis of stem-like ALDHhiCD44+ human breast
cancer cells. The work presented in this thesis aimed to further build on these findings by
investigating the potential role of the lung microenvironment in promoting a stem-like
phenotype once the breast cancer cells reach the secondary site of metastasis. In doing so,
we discovered that lung-CM not only decreased the proportion of cells expressing the stemlike ALDHhiCD44+ phenotype, but also reduced the expression of several other genes
related to stemness. Utilizing a discovery based approach, arrays composed of human
cancer stem cells genes highlighted the effect lung-CM treatment has on human breast
cancer cells. Collectively, we identified five genes that were affected by lung-CM
treatment in both adherent and non-adherent cell subpopulation. Notably, genes related to
a stem-like phenotype in breast cancer cells, CD24 and MUC1, were significantly
downregulated in response to lung-CM. As a heavily glycosylated adhesion molecule,
CD24 has been implicated in progression and metastatic spread of several cancers. In a
meta-analysis conducted by Lee et al, CD24 expression was more frequently and highly
expressed in malignant tumours of the breast and ovaries, relative to their benign
counterparts227. Moreover, elevated levels of CD24 expression have been associated with
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tumour progression and metastasis when investigating its role as a molecular marker of
CSCs143. Although it remains a controversial subject, some studies have reported a
decrease in CD24 protein expression in stem-like progenitor cells relative to differentiated
cells143. We also observed a decrease in MUC1 gene expression following exposure to
lung-CM. With its role in the expansion of pluripotent human embryonic stem cells, MUC1
has been shown to be overexpressed in both ER+ and ER- breast cancers, in addition to its
association with breast cancer cell side populations identified via exclusion of Hoechst
33342 stain144. Together with a decrease in stem-like ALDHhiCD44+ breast cancer cell
phenotype and impaired mammosphere formation, the decrease in CD24 and MUC1 gene
expression in response to the lung microenvironment supports the idea that stemness is
being lost in these human breast cancer cells.
Despite observations that support diminished stem-like phenotype and behaviour,
treatment with lung-CM affected the expression of several other genes related to increased
aggressiveness. For example, both ATM and WEE1 were significantly downregulated in
response to lung-CM. These genes represent a class of tumour signaling molecules
involved in cell cycle control and have been implicated numerous times to have a role in
cancer development. ATM is a serine/threonine kinase that has a central role in recognition
of DNA damage, and responds accordingly by repairing double-stranded DNA breaks.
Interestingly, in a study investigating 385 patients with gastric cancer, Han et al report a
downregulation of ATM mRNA expression within tumour samples, relative to adjacent
healthy tissue150. In addition, Kaplan-Meier analysis demonstrated patients with ATMnegative tumours had a drastically lower survival rate compared to ATM-positive
tumours150. Similarly, increased ATM gene expression in breast carcinomas has been
associated with a favorable patient outcome and prognosis151. WEE1 is also a
serine/threonine kinase that is involved in regulating G2-M cell cycle checkpoint. The main
role of WEE1 is to arrest mitotic entry in response to DNA damage, and its impairment has
led to the loss of DNA-damage induced apoptosis and aberrant mitosis, however its role in
carcinogenesis remains controversial146. Studies that have successfully inhibited WEE1
activity report an anticarcinogenic role in basal and TN breast cancer cells, while WEE1
overexpression in both melanoma and vulvar squamous cell carcinoma have been
associated with poor disease-free survival and malignancy228-231. Although there is not a
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clear consensus on the role of WEE1 in tumour development, it is likely that a decrease in
gene expression of ATM and/or WEE1 may contribute to heightened malignancy due to
loss of cell cycle control, despite the decrease in stemness.
Of the five genes of interest that were consistently affected by lung-CM treatment in both
adherent and non-adherent breast cancer subpopulations, the only gene that exhibited an
increase in expression was metastasis/migration related CXCL8, a precursor to interleukin
8 (IL8). Originally identified as a monocyte-derived factor, IL8 has been reported to recruit
and activate neutrophils to site of inflammation, as well as the propagation of epithelial-tomesenchymal transition in human cancer cells147,148. In breast cancer, IL8 expression is
significantly increased in more aggressive ER- subtypes and has been reported to promote
metastasis through increased cell invasion and angiogenesis148,232. Again, this data suggests
that although lung-CM diminishes stem-like phenotype and behavior, it may still support
metastatic capacity through mechanisms such as increased motility and cell recruitment.
Many studies have documented the importance of ALDH activity in combination with cell
surface markers, such as CD44, to isolate populations of cancer cells that behave in an
aggressive manner both in vitro and in vivo. The unexpected findings of this thesis do not
discredit the tumourigenic potential of stem-like cell populations, but instead suggest that
stem-like characteristics are not compulsory for tumour development once in the secondary
lung microenvironment. Our gene array analysis demonstrates that CSC-related genes were
downregulated, along with the downregulation of tumour signaling molecules involved in
cell cycle regulation. Moreover, the upregulation of CXCL8 suggests the soluble lung
microenvironment may promote cell migration. Taken together, although stemness of
breast cancer cells is decreased after exposure to lung-CM, these cells may still retain
metastatic capacity in order to drive disease progression in a CSC-independent manner.
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Possible Limitations of the Study
The model system used in this thesis is based on an ex vivo representation of the soluble
organ microenvironment, and with this, is an imperfect model that relies on several
assumptions.
The first assumption is that breast cancer metastasis is primarily influenced by the soluble
organ microenvironment. Several studies have recently addressed the importance of the
insoluble organ microenvironment in providing the necessary infrastructure for tumour
development, with parameters such as scaffold composition, density, pore size, and elastic
modulus affecting in vitro tumour development233,234. Thus, to more accurately depict the
role of the entire organ microenvironment regarding preferential metastasis and stemness
in vitro, it would be necessary to incorporate both soluble and insoluble components.
The second assumption is that the composition of the lung-CM media will truly reflect the
soluble lung microenvironment. During the process of generating lung-CM, murine lungs
are mechanically dissociated to allow soluble proteins to be secreted into the culture
medium. Although the proteins that make their way into the conditioned media are specific
to the lung tissue, they are not necessarily all natively secreted proteins and many would
generally remain confined within the cell of origin in vivo. During the dissociation process,
cells of the lung are forcibly lysed and their contents released into the culture medium,
resulting in a lung-CM that is enriched in both intracellular and extracellular related
proteins. We observed that 86.6% of proteins within the lung-CM belong to the
intracellular compartment. This is not an issue with BM-CM as its generation requires
several passages that likely discard any intracellular contents that may be present due to
cell lysis. An improved method for generating lung-CM would be one that is less prone to
cell lysis, such as using bead mill homogenizers235.
The third assumption is that breast cancer cells and their associated stem-like
characteristics will behave in a similar manner when exposed to lung-CM derived from
either healthy or diseased lung tissue. As our study utilizes healthy murine tissue to
generate lung and BM-CM, there is the potential that we are not presenting a fully accurate
model for metastasis to secondary organs in a host that first developed a primary tumor.
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The concept of metastatic priming has been recently introduced and supported by several
studies; whereby the presence of a primary tumour may “prime” the microenvironment of
a distant secondary organ prior to the arrival of metastatic cancer cells236-238. Permitting
tumour development following orthotopic injection of human breast cancer cells into the
mammary fat pad of mice could allow potential “priming” mechanism to influence the
microenvironments of secondary sites of metastasis.
The fourth assumption is with regards to our animal model and generation of organ-CM.
Primarily, we utilized an immunocompromised murine model to generate our organ-CM
treatments as future studies would utilize the inherent NOD/SCID mutation to improve
rates of human tissue engraftment in vivo. Due to their reduced innate immunity (NOD
mutation) and complete T- and B-cell deficiency (SCID mutation), these mutations may
have noticeable effects on the lung tissue239. Within the lower respiratory tract, alveolar
macrophages represent the largest population of leukocytes in healthy lung tissue capable
of ingesting microbes, and, initiating an immune response by presenting cell surface
antigens240. Thus, it is likely these alveolar macrophages (among other immune cells) are
significantly reduced in our model of the healthy lung and may be beneficial to utilize an
immunocompetent model instead. Further, CO2 asphyxiation was carried out during
euthanasia. This method helps to maintain our lung samples intact post-euthanasia,
however may damage the microarchitecture within the lung tissue. It has been reported that
rapid asphyxia with CO2 results in alveolar atrophy and hemorrhaging within murine lungs,
thus compromising the native state of healthy lungs within our model241. An alternative
approach could be euthanization by retroorbital ketamine-xylazine injections242. Although
this method may appear distasteful, it is more humane than other IV injections and better
conserves the integrity of lung tissue by avoiding asphyxiation242.
The final assumption concerns the use of immortalized cell lines. Although cell lines are
routinely used in the cancer research community, their behaviour and intrinsic mechanisms
can become altered over successive passages and the foreign in vitro culture conditions.
The breast cancer cell lines used in this study were once derived from individual primary
patient samples, however their immortalization is linked to inherent mutations that allow
for continuous growth outside of their native microenvironment. Preferably, a model
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utilizing primary breast cancer cells would more accurately depict the underlying
biological processes of cancer pertaining to phenotype and behaviour243.
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Future Directions
While this thesis investigated several important questions pertaining to stem-like breast
cancer phenotype and function in response to the lung and bone microenvironments, there
are several avenues of investigation that need to be addressed in future studies to better
understand the role of these organ microenvironments in metastasis.
First, as lung-CM treatment decreased cell surface CD44 expression and induced a nonadherent breast cancer subpopulation incapable of mammosphere formation, it is important
to investigate whether these cells have lost adhesive properties through CD44-mediated
interactions. A potential resolution could be to coat tissue culture plastic with a known
CD44 receptor ligand, such as OPN, and monitor whether non-adherent breast cancer cells
retain their capacity to re-adhere when provided suitable conditions. If the breast cancer
cells remain non-adherent after exposure to a known ligand, one can infer that loss of cell
surface CD44 may not be responsible for the non-adherent phenotype.
Second, as we only investigated the composition of the lung-CM, it is necessary to perform
similar analysis on the BM-CM. Understanding which factors are present within the BMCM would provide insight into the effects that BM-CM imposed on our adherent and nonadherent breast cancer cell subpopulations. Furthermore, by assessing the composition of
BM-CM, we would be able to effectively compare which proteins are similar or different
between the lung-CM and BM-CM models.
Third, considering the BM is a rich stem cell niche for hematopoietic stem cells, it would
be interesting to investigate whether CSC-related genes are affected in breast cancer cells
after treatment with BM-CM. Using a similar human cancer stem cell gene array used for
lung-CM analysis, some insight would be provided with regards to changes in CSC gene
expression and whether similar genes were affected by both lung-CM and BM-CM.
Finally, future studies must move these findings into an in vivo model. Recapitulating the
native organ microenvironment in vitro is a significant feat, and often, those who attempt
its representation experience shortcomings. Although many studies highlight the
tumourigenic and metastatic potential of stem-like cancer cells, our study indicates that the
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stem-like phenotype may be diminished once breast cancer cells are exposed to the lung
microenvironment. However, the induction of a viable, non-adherent population of breast
cancer cells with gene expression patterns suggestive of increased migratory and/or
metastatic capacity warrants further investigation of the true functional effect of these cells
in vivo, independent of the CSC context.
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Final Conclusions
The purpose of this thesis was to test the hypothesis that the lung and/or bone
microenvironments could promote stem-like phenotype and function in human breast
cancer cells. As metastasis is the leading cause of cancer-related deaths, it is of utmost
importance to strengthen our understanding of tumour dissemination and development at
distant secondary sites. Prior to this study, our lab has focused on the “getting there”
perspective of metastasis and have demonstrated that the lung microenvironment can
promote chemotactic migration in both whole cell populations and sorted ALDHhiCD44+
stem-like human breast cancer cell populations. Here, we have begun investigation into the
“establishment” stage of tumour metastasis. In particular, this thesis has directed attention
to breast cancer cell stemness and plasticity, investigating whether the secondary
microenvironment can mediate stem-like attributes associated with the CSC theory of
cancer development.

Taken together, our findings (summarized in Table 6) did not support the hypothesis of
this thesis. Treatment with lung-CM decreased stem-like characteristics, namely ALDH
and CD44 phenotype. Further, these cells were not capable of producing mammospheres,
which is also a common in vitro measure of stemness. Despite these findings, evidence in
the literature also supports the notion that cancer cells with decreased ALDH activity and
CD44 expression can be more tumourigenic and correlate with advanced stage cancers.
Further, our data suggests that the migration related gene, CXCL8, is upregulated after
lung-CM treatment, while CSC markers (CD24 and MUC1) and tumour signaling
molecules (ATM and WEE1) are downregulated. Previous studies in our lab provide
evidence that lung-CM supports existing ALDHhiCD44+ cells, with respect to migration
and growth, however the findings of this thesis indicates that neither lung-CM or bone-CM
actually promote stemness of breast cancer cells. Nonetheless, we did uncover an intriguing
non-adherent, viable subpopulation of breast cancer cells that are induced by lung-CM, and
this population will be important to investigate further in the future to determine if and how
the lung microenvironment may promote survival and migration of breast cancer cells
using mechanisms distinct from CSC pathways.
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APPENDICES

Appendix 1. Approved animal use protocol

AUP Number: 2009-064
PI Name: Allan, Alison
AUP Title: Role of ALDH+/CD44+ stem-like cells in breast cancer progression and treatment
Approval Date: 10/27/2017
Official Notice of Animal Care Committee (ACC) Approval:
Your new Animal Use Protocol (AUP) 2009-064:9: entitled " Role of ALDH+/CD44+ stem-like cells in breast cancer progression and treatment"
has been APPROVED by the Animal Care Committee of the University Council on Animal Care. This approval, although valid for up to four years,
is subject to annual Protocol Renewal.
Prior to commencing animal work, please review your AUP with your research team to ensure full understanding by everyone listed within this
AUP.
As per your declaration within this approved AUP, you are obligated to ensure that:
1) Animals used in this research project will be cared for in alignment with:
a) Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.html
b) University Council on Animal Care Policies and related Animal Care Committee procedures
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies.htm
2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including permits and scientific/ departmental peer approvals, are complete and accurate;
c) any divergence from this AUP will not be undertaken until the related Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full AUP Renewals - will be submitted and attended to within timeframes outlined by
the ACC.
e) http://uwo.ca/research/services/animalethics/animal_use_protocols.html
3) As per MAPP 7.10 all individuals listed within this AUP as having any hands-on animal contact will
a) be made familiar with and have direct access to this AUP;
b) complete all required CCAC mandatory training (training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures will be followed, including but not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visits
5) As per institutional OH&S policies, all individuals listed within this AUP who will be using or potentially exposed to hazardous materials will
have completed in advance the appropriate institutional OH&S training, facility-level training, and reviewed related (M)SDS Sheets,
http://www.uwo.ca/hr/learning/required/index.html
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care

Dr.Timothy Regnault,
Animal Care Committee Chair
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Appendix 2. Exposure to organ-CM did not affect protein expression of ALDH1A3 in
human breast cancer cells. MDA-MB-468 human breast cancer cells were exposed to
lung-CM, BM-CM, and basal control for 72 hours. Both adherent and non-adherent
subpopulations were harvested and cell lysates utilized for analysis of ALDH1A3 protein
expression by western blot. (A) Treatment with either lung-CM or BM-CM did not affect
ALDH1A3 protein expression relative to basal media. All data are normalized to the basal
control group and β-Actin. (B) Representative cropped image of western blot probing for
ALDH1A3 (56 KDa) and β-Actin (42 KDa). Lanes are labelled based on treatment
condition received (lung, bone, or basal) and associated with either adherent (A) or nonadherent (N-A) subpopulations. Experiments were performed a minimum of 3 times and
analyses were performed using 2-way ANOVA and Dunnett’s post hoc test. Data is
presented as mean ± SEM. All significant values (*) are relative to the respective treatments
adherent population (p<0.05).
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Appendix 3. Relative mRNA expression levels of cell lines and cell subpopulations in
response to basal media. MDA-MB-468 (Adherent and Non-adherent subpopulations)
and SUM159 cells were exposed to basal media for 24 hours in culture (37°C, 5% CO2)
without media replacement. Cells were harvested and RNA was analyzed by RT-qPCR to
assess expression of CD44, ALDH1A1 and ALDH1A3. All analyses were normalized to
GAPDH expression and shown as relative expression levels. Experiments were performed
a minimum of three times and statistical analyses were performed using one-way ANOVA
and Dunnett’s post hoc test. Data is presented as mean ± SEM. All significant values (*)
are relative to the SUM159 cell line with each gene respectively (p<0.05, N=3).
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Appendix 4. Average Ct values of MDA-MB-468 cells following qRT-PCR Human
Cancer Stem Cell gene array analysis. Adherent (A) and Non-adherent (NA) cell
subpopulations were analyzed and data sets are colour-coded based on subpopulations
being compared: Basal-A vs Basal-NA (Black), Lung-A vs Lung-NA (Blue), Basal-NA vs
Lung-NA (Orange), and Basal-A vs Lung-A (Green). Raw data acquired using Qiagen’s
Data Analysis Center® software.
Gene
Name

Average Ct Values
Basal – A Basal – NA Lung – A Lung – NA Basal – NA Lung – NA Basal – A
(Control) (Sample) (Control) (Sample) (Control) (Sample) (Control)

Lung – A
(Sample)

ABCB5

40

40

40

40

40

40

40

40

ABCG2

40

40

39.53

39.68

40

39.68

40

39.53

ALCAM

25.56

26.39

26.29

28.04

26.39

28.04

25.56

26.29

ALDH1A1

25.12

25.75

25.74

27.5

25.75

27.5

25.12

25.74

ATM

30.93

30.9

32.76

33.78

30.9

33.78

30.93

32.76

ATXN1

27.01

27.78

28.4

30.12

27.78

30.12

27.01

28.4

AXL

35.02

32.52

31.51

32.87

32.52

32.87

35.02

31.51

BMI1

27.22

27.58

27.41

28.92

27.58

28.92

27.22

27.41

BMP7

30.92

31.59

30.29

31.85

31.59

31.85

30.92

30.29

CD24

25.96

27.03

28.53

29.32

27.03

29.32

25.96

28.53

CD34

40

38.81

40

39.84

38.81

39.84

40

40

CD38

35.99

34.74

35.95

37.12

34.74

37.12

35.99

35.95

CD44

22.59

23.05

22.22

23.5

23.05

23.5

22.59

22.22

CHEK1

26.6

28.08

27.15

29.19

28.08

29.19

26.6

27.15

DACH1

34.13

35.52

36.2

38.86

35.52

38.86

34.13

36.2

DDR1

26.66

27.16

26.46

28.2

27.16

28.2

26.66

26.46
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DKK1

28.29

29.47

30.32

30.83

29.47

30.83

28.29

30.32

DLL1

40

37.79

38.62

39.15

37.79

39.15

40

38.62

DLL4

40

38.61

40

38.33

38.61

38.33

40

40

DNMT1

25.46

26.11

25.5

27.31

26.11

27.31

25.46

25.5

EGF

31.25

30.82

30.68

32.72

30.82

32.72

31.25

30.68

ENG

30.4

30.53

29.88

31.29

30.53

31.29

30.4

29.88

EPCAM

23.48

24.17

23.64

25.16

24.17

25.16

23.48

23.64

ERBB2

29.76

30.28

29.76

31.76

30.28

31.76

29.76

29.76

ETFA

23.78

24.83

24.75

26.29

24.83

26.29

23.78

24.75

FGFR2

29.32

29.98

29.35

31.33

29.98

31.33

29.32

29.35

FLOT2

26.37

26.75

26.28

27.95

26.75

27.95

26.37

26.28

FOXA2

40

40

39.43

39.67

40

39.67

40

39.43

FOXP1

28.96

29.32

29.41

30.82

29.32

30.82

28.96

29.41

FZD7

30.01

30

30.17

31.3

30

31.3

30.01

30.17

GATA3

29.5

30.17

29.76

31.51

30.17

31.51

29.5

29.76

GSK3B

26.29

26.65

26.62

28.26

26.65

28.26

26.29

26.62

HDAC1

25.15

25.53

25.57

27.25

25.53

27.25

25.15

25.57

ID1

27.27

28.25

25.79

27.88

28.25

27.88

27.27

25.79

IKBKB

29.59

29.54

29.29

30.59

29.54

30.59

29.59

29.29

CXCL8

32.66

29.2

29.17

28.09

29.2

28.09

32.66

29.17

ITGA2

29.89

30.04

28.81

30.13

30.04

30.13

29.89

28.81

ITGA4

38.52

40

40

40

40

40

38.52

40
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ITGA6

27.36

27.75

26.44

28.72

27.75

28.72

27.36

26.44

ITGB1

26.49

27.04

26.3

28.37

27.04

28.37

26.49

26.3

JAG1

27.88

28.1

26.14

27.7

28.1

27.7

27.88

26.14

JAK2

31.17

31.56

31.22

33.46

31.56

33.46

31.17

31.22

KIT

33.24

35.12

38.82

38.85

35.12

38.85

33.24

38.82

KITLG

27.15

28.01

28.18

30.64

28.01

30.64

27.15

28.18

KLF17

37.08

34.83

35.36

36.83

34.83

36.83

37.08

35.36

KLF4

29.35

29.58

28.56

30.38

29.58

30.38

29.35

28.56

LATS1

28.38

28.78

28.65

30.5

28.78

30.5

28.38

28.65

LIN28A

34.14

33.21

35.45

36.18

33.21

36.18

34.14

35.45

LIN28B

38.76

40

40

39.16

40

39.16

38.76

40

MAML1

30.47

30.73

30.6

32.32

30.73

32.32

30.47

30.6

MERTK

34.74

33.79

33.44

35.48

33.79

35.48

34.74

33.44

MS4A1

40

40

40

40

40

40

40

40

MUC1

26.52

26.97

28.37

30.15

26.97

30.15

26.52

28.37

MYC

24.12

25.47

24.21

26.25

25.47

26.25

24.12

24.21

MYCN

31.68

33.42

33.29

36.35

33.42

36.35

31.68

33.29

NANOG

38.63

35.79

40

38.63

35.79

38.63

38.63

40

NFKB1

29.32

29.66

29.01

31.23

29.66

31.23

29.32

29.01

NOS2

38.34

35.4

36.73

39.26

35.4

39.26

38.34

36.73

NOTCH1

31.55

32.05

31.28

32.86

32.05

32.86

31.55

31.28

NOTCH2

27.18

27.81

28.14

30.15

27.81

30.15

27.18

28.14
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PECAM1

36.08

35.63

36.83

38.08

35.63

38.08

36.08

36.83

PLAT

39.97

38.59

37.39

38.77

38.59

38.77

39.97

37.39

PLAUR

27.63

27.68

26.39

27.59

27.68

27.59

27.63

26.39

POU5F1

33.03

31.71

32.77

33.68

31.71

33.68

33.03

32.77

PROM1

25.86

26.44

27.03

28.54

26.44

28.54

25.86

27.03

PTCH1

33.8

35.36

34.17

37.1

35.36

37.1

33.8

34.17

PTPRC

38.74

40

40

39.32

40

39.32

38.74

40

SAV1

25.76

26.89

25.94

28.07

26.89

28.07

25.76

25.94

SIRT1

27.41

27.89

27.73

29.51

27.89

29.51

27.41

27.73

SMO

32.91

33.59

34.17

35.33

33.59

35.33

32.91

34.17

SNAI1

37.26

35.13

38.13

37.16

35.13

37.16

37.26

38.13

SOX2

40

40

40

40

40

40

40

40

STAT3

24.81

25.44

25.1

26.86

25.44

26.86

24.81

25.1

TAZ

27.96

27.92

27.29

29.02

27.92

29.02

27.96

27.29

TGFBR1

27.09

27.34

26.84

28.71

27.34

28.71

27.09

26.84

THY1

35.94

37.51

37.71

38.32

37.51

38.32

35.94

37.71

TWIST1

38.82

40

39.02

40

40

40

38.82

39.02

TWIST2

30.16

30.83

29.63

31.47

30.83

31.47

30.16

29.63

WEE1

26.15

27.06

27.7

29.88

27.06

29.88

26.15

27.7

WNT1

40

39.42

40

40

39.42

40

40

40

WWC1

26.62

27.05

26.55

28.57

27.05

28.57

26.62

26.55

YAP1

25.26

25.75

25.29

27.24

25.75

27.24

25.26

25.29
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ZEB1

39.04

37.05

36.51

38.43

37.05

38.43

39.04

36.51

ZEB2

40

40

40

40

40

40

40

40

ACTB

19.57

20.46

19.95

21.43

20.46

21.43

19.57

19.95

B2M

23.37

24.49

24.66

26.14

24.49

26.14

23.37

24.66

GAPDH

21.11

22.05

21.52

22.65

22.05

22.65

21.11

21.52

HPRT1

26.48

27.41

27.43

29.04

27.41

29.04

26.48

27.43

RPLP0

19.55

20.21

20.19

21.47

20.21

21.47

19.55

20.19

HGDC

38.61

40

40

40

40

40

38.61

40

RTC

21.91

22.15

22.42

22.23

22.15

22.23

21.91

22.42

RTC

22.02

22.19

22.52

22.27

22.19

22.27

22.02

22.52

RTC

21.97

22.17

22.42

22.15

22.17

22.15

21.97

22.42

PPC

19.87

19.92

20.05

20.01

19.92

20.01

19.87

20.05

PPC

19.57

19.78

20

19.86

19.78

19.86

19.57

20

PPC

19.88

20.08

20.01

19.99

20.08

19.99

19.88

20.01
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